<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:z="http://www.zotero.org/namespaces/export#"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:bib="http://purl.org/net/biblio#"
 xmlns:foaf="http://xmlns.com/foaf/0.1/"
 xmlns:link="http://purl.org/rss/1.0/modules/link/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368682/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1948-7193"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6006"/>
        <dc:title>(S)-(+)-Mecamylamine (TC-5214): A Neuronal Nicotinic Receptor Modulator Enters Phase III Trials as an Adjunct Treatment for Major Depressive Disorder (MDD)</dc:title>
        <bib:pages>530-531</bib:pages>
        <dc:date>2010-08-18</dc:date>
        <z:shortTitle>(S)-(+)-Mecamylamine (TC-5214)</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368682/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778844
PMCID: PMC3368682</dc:description>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1948-7193">
        <dc:title>ACS Chemical Neuroscience</dc:title>
        <prism:volume>1</prism:volume>
        <prism:number>8</prism:number>
        <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
        <dc:identifier>DOI 10.1021/cn100070s</dc:identifier>
        <dc:identifier>ISSN 1948-7193</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_6006">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368682/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368691/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>9</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000809</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_6446"/>
        <dc:title>A Small Molecule Which Protects Newborn Neurons</dc:title>
        <dcterms:abstract>, New research identifies a small molecule providing a chemical scaffold
which might be useful in the design of a new class of neuroprotective
drugs.</dcterms:abstract>
        <bib:pages>589</bib:pages>
        <dc:date>2010-09-15</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368691/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778848
PMCID: PMC3368691</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6446">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368691/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368669/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100028b</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_6791"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight</dc:title>
        <bib:pages>257</bib:pages>
        <dc:date>2010-04-21</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368669/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368669</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6791">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368669/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368692/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>9</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000588</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8076"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight on Dimebon</dc:title>
        <dcterms:abstract>, Dimebon (latrepirdine) is an antihistamine drug that has been used clinically in Russia since the early 1980s and is being studied jointly by Pfizer and Medivation for patients with Alzheimer’s disease. The results from a pivotal Phase 3 clinical trial (CONNECTION) showed that Dimebon (latrepirdine) failed to meet its coprimary or secondary efficacy end points.</dcterms:abstract>
        <bib:pages>587-588</bib:pages>
        <dc:date>2010-09-15</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368692/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778847
PMCID: PMC3368692</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8076">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368692/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368683/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>6</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100024g</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8654"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight on Fanapt</dc:title>
        <dcterms:abstract>, The new mixed dopamaine D2/serotonin 5-HT2A antagonist, Fanapt (iloperidone), was approved by the FDA on May 6th, 2009 for the treatment of schizophrenia in adults.</dcterms:abstract>
        <bib:pages>410</bib:pages>
        <dc:date>2010-06-16</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368683/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778835
PMCID: PMC3368683</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8654">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368683/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368635/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>11</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100059u</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8428"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight on Lorcaserin</dc:title>
        <dcterms:abstract>, Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine2C (5-HT2C) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.</dcterms:abstract>
        <bib:pages>718-719</bib:pages>
        <dc:date>2010-11-17</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368635/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778808
PMCID: PMC3368635</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8428">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368635/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368665/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>7</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100025k</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7684"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight on Sabril</dc:title>
        <dcterms:abstract>, Sabril (vigabatrin) oral solution was approved by the FDA on August 21st, 2009 for treatment of infantile spasms in children ages 1 month to 2 years and complex partial seizures in adults (tablets).</dcterms:abstract>
        <bib:pages>475</bib:pages>
        <dc:date>2010-07-21</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368665/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778839
PMCID: PMC3368665</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7684">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368665/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368668/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100022a</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8942"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight on Saphris</dc:title>
        <dcterms:abstract>, On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously. Saphris (asenapine) is a multitarget atypical antipsychotic medication approved to treat adults with schizophrenia and bipolar I disorder.</dcterms:abstract>
        <bib:pages>263-264</bib:pages>
        <dc:date>2010-04-21</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368668/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778826
PMCID: PMC3368668</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8942">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368668/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368631/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>10</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100061r</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7157"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight on Saredutant</dc:title>
        <dcterms:abstract>, Saredutant (SR48968), a potentially novel treatment option for major depressive disorders (MDD) and generalized anxiety disorder (GAD), is a drug from Sanofi-Aventis currently in phase III clinical trials. MDD is a common mental disorder that affects 121 million people worldwide, nearly 4% of the adult population (www.who.int/mental_health/management/depression/definition/en/). MDD continues to be one of the leading causes of disability with more than three quarters of the diagnosed cases having effective treatments available (www.who.int/mental_health/management/depression/definition/en/). However, even though MDD affects a large portion of the population, effective treatment options with low incidence of adverse events remain a major concern for the pharmaceutical industry. Adverse events (GI side effects1, weight gain, somnolence/insomnia, etc. (DemyttenaereK. (2003) Risk factors and predictors of compliance in depressionEur. Neuropshychopharm.13S69−S75)) from the typical treatments remain the major reason for premature stopping or poor compliance of treatment. New treatments to the market must bear in mind these adverse events, and the pharmaceutical industry is currently looking for drugs with new mechanisms of action and those that are better tolerated.</dcterms:abstract>
        <bib:pages>653-654</bib:pages>
        <dc:date>2010-10-20</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368631/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22776916
PMCID: PMC3368631</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7157">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368631/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368674/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>5</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000233</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7456"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight on Savella</dc:title>
        <dcterms:abstract>, Savella (milnacipran), a selective serotonin and noradrenaline reuptake inhibitor, was approved by the FDA on January 14th, 2009, for the treatment of fibromyalgia.</dcterms:abstract>
        <bib:pages>345</bib:pages>
        <dc:date>2010-05-19</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368674/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778830
PMCID: PMC3368674</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7456">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368674/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368681/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>8</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000606</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7219"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight on Semagacestat (LY450139)</dc:title>
        <dcterms:abstract>, Semagacestat (LY450139) is a novel γ-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer’s disease (AD). Semagacestat is currently being studied in two phase III clinical trials.</dcterms:abstract>
        <bib:pages>533-534</bib:pages>
        <dc:date>2010-08-18</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368681/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778845
PMCID: PMC3368681</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7219">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368681/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368641/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>12</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100062j</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7178"/>
        <dc:title>ACS Chemical Neuroscience Molecule Spotlight on Valdoxen</dc:title>
        <dcterms:abstract>, A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT2C receptor.</dcterms:abstract>
        <bib:pages>772-773</bib:pages>
        <dc:date>2010-12-15</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368641/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778814
PMCID: PMC3368641</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7178">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368641/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369704/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000793</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sweeney</foaf:surname>
                        <foaf:givenname>Zachary K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lewcock</foaf:surname>
                        <foaf:givenname>Joseph W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6244"/>
        <dc:title>ACS Chemical Neuroscience Spotlight on CEP-1347</dc:title>
        <bib:pages>3-4</bib:pages>
        <dc:date>2010-09-03</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369704/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778853
PMCID: PMC3369704</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6244">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369704/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016054/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>12</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100037d</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pajski</foaf:surname>
                        <foaf:givenname>Megan L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Venton</foaf:surname>
                        <foaf:givenname>B. Jill</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7008"/>
        <dc:title>Adenosine Release Evoked by Short Electrical Stimulations in Striatal Brain Slices Is Primarily Activity Dependent</dc:title>
        <dcterms:abstract>, Adenosine is an important neuromodulator in the brain. Traditionally, adenosine is thought to arise in the extracellular space by either an extracellular mechanism, where it is formed outside the cell by the breakdown of released ATP, or an intracellular mechanism, where adenosine made inside the cell is transported out. Recently, a third mechanism of activity dependent adenosine release has also been proposed. Here, we used fast-scan cyclic voltammetry to compare the time course and mechanism of adenosine formation evoked by either low- or high-frequency stimulations in striatal rat brain slices. Low-frequency stimulations (5 pulses at 10 Hz) resulted in an average adenosine efflux of 0.22 ± 0.02 μM, while high-frequency stimulations (5 pulses, 60 Hz) evoked 0.36 ± 0.04 μM. Blocking intracellular formation by inhibiting adenosine transporters with S-(4-nitrobenzyl)-6-thioinosine (NBTI) or propentofylline did not decrease release for either frequency, indicating that the release was not due to the intracellular mechanism. Blocking extracellular formation with ARL-67156 reduced low-frequency release about 60%, but did not affect high-frequency release. Both low- and high-frequency stimulated release were almost completely blocked by the removal of calcium, indicating activity dependence. Reducing dopamine efflux did not affect adenosine release but inhibiting ionotropic glutamate receptors did, indicating that adenosine release is dependent on downstream effects of glutamate. Therefore, adenosine release after short, high-frequency physiological stimulations is independent of transporter activity or ATP metabolism and may be due to the direct release of adenosine after glutamate receptor activation.</dcterms:abstract>
        <bib:pages>775-787</bib:pages>
        <dc:date>2010-10-13</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016054/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21218131
PMCID: PMC3016054</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7008">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016054/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368666/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>7</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100031t</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Speed</foaf:surname>
                        <foaf:givenname>Nicole K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Matthies</foaf:surname>
                        <foaf:givenname>Heinrich J. G.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kennedy</foaf:surname>
                        <foaf:givenname>J. Phillip</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vaughan</foaf:surname>
                        <foaf:givenname>Roxanne A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Javitch</foaf:surname>
                        <foaf:givenname>Jonathan A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Russo</foaf:surname>
                        <foaf:givenname>Scott J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Niswender</foaf:surname>
                        <foaf:givenname>Kevin</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Galli</foaf:surname>
                        <foaf:givenname>Aurelio</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9187"/>
        <dc:title>Akt-Dependent and Isoform-Specific Regulation of Dopamine Transporter Cell Surface Expression</dc:title>
        <dcterms:abstract>, Dopamine (DA) is a neurotransmitter implicated in multiple functions, including movement, cognition, motivation, and reward. The DA transporter (DAT) is responsible for clearing extracellular DA, thereby terminating DA neurotransmission. Previously, it has been shown that insulin signaling through protein kinase B/Akt regulates DAT function by fine-tuning DAT cell surface expression. Importantly, specific Akt isoforms (e.g., Akt1, Akt2) serve distinct physiological functions. Here, we demonstrate using isoform-specific Akt inhibitors that basal activity of Akt2, rather than Akt1, regulates DAT cell surface expression. Since Akt2 activation is mediated by insulin, these data further implicate insulin signaling as an important modulator of DAT function and dopaminergic tone.</dcterms:abstract>
        <bib:pages>476-481</bib:pages>
        <dc:date>2010-05-25</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368666/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778840
PMCID: PMC3368666</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9187">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368666/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368626/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900015v</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hellstrand</foaf:surname>
                        <foaf:givenname>Erik</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Boland</foaf:surname>
                        <foaf:givenname>Barry</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Walsh</foaf:surname>
                        <foaf:givenname>Dominic
M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Linse</foaf:surname>
                        <foaf:givenname>Sara</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8842"/>
        <dc:title>Amyloid ?-Protein Aggregation Produces Highly Reproducible Kinetic Data and Occurs by a Two-Phase Process</dc:title>
        <dcterms:abstract>, Protein aggregation can lead to major disturbances of cellular
processes and is associated with several diseases. We report kinetic
and equilibrium data by ThT fluorescence and enzyme-linked immunosorbent
assay of sufficient quality and reproducibility to form a basis for
mechanistic understanding of amyloid β-peptide (Aβ) fibril
formation. Starting from monomeric peptide in a pure buffer system
without cosolvents, we find that the kinetics of Aβ aggregation
vary strongly with peptide concentration in a highly predictable manner.
The free Aβ concentration in equilibrium with fibrils was found
to vary with total peptide concentration in a manner expected for
a two-phase system. The free versus total Aβ concentration was
linear up to ca. 0.2 μM, after which free Aβ decreased
with total Aβ toward an asymptotic value. Our results imply
that Aβ fibril formation arises from a sequence of events in
a highly predictable manner.</dcterms:abstract>
        <bib:pages>13-18</bib:pages>
        <dc:date>2009-10-09</dc:date>
        <z:shortTitle>Amyloid ?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368626/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778803
PMCID: PMC3368626</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8842">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368626/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992454/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>10</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100067e</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhao</foaf:surname>
                        <foaf:givenname>Xiaobei</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yang</foaf:surname>
                        <foaf:givenname>Jerry</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9138"/>
        <dc:title>Amyloid-? Peptide Is a Substrate of the Human 20S Proteasome</dc:title>
        <dcterms:abstract>, Intraneuronal accumulation of ubiquitin conjugates is a pathological feature of neurodegenerative disorders such as Alzheimer’s disease (AD). Previous reports propose that accumulation of ubiquitinated species in AD is a result of inhibition of proteasomal activity by amyloid-β (Aβ) peptides, which leads to blocking of ubiquitin-dependent protein degradation by the proteasome. Here, we provide additional insight into proteasomal dysfunction by Aβ peptides by revealing that aggregated forms of Aβ(1−42) peptides (especially small oligomers) are, in fact, competitive substrates for the chymotrypsin-like activity of the human 20S (h20S) proteasome. In addition to examining the kinetics of the h20S proteasome activity in the presence or absence of Aβ peptides, we use gel electrophoresis, LC-MS, and TOF-MS/MS analyses to examine the degradation of Aβ(1−42) by the h20S proteasome. The observed peptide fragments resulting from proteolytic cleavage of Aβ were consistent with predicted cleavage sites from proteasome degradation. These results support that the interaction of Aβ peptides with the proteasome may play a mechanistic role in proteasomal dysfunction in AD pathology. These results may also reveal a previously unknown natural pathway for clearance of Aβ in normal or diseased cells.</dcterms:abstract>
        <bib:pages>655-660</bib:pages>
        <dc:date>2010-08-25</dc:date>
        <z:shortTitle>Amyloid-?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992454/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21116456
PMCID: PMC2992454</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9138">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992454/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400287/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000974</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Green</foaf:surname>
                        <foaf:givenname>Brad R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Smith</foaf:surname>
                        <foaf:givenname>Misty</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>White</foaf:surname>
                        <foaf:givenname>Karen L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>White</foaf:surname>
                        <foaf:givenname>H. Steve</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bulaj</foaf:surname>
                        <foaf:givenname>Grzegorz</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7995"/>
        <dc:title>Analgesic Neuropeptide W Suppresses Seizures in the Brain Revealed by Rational Repositioning and Peptide Engineering</dc:title>
        <dcterms:abstract>, Anticonvulsant neuropeptides play an important role in controlling neuronal excitability that leads to pain or seizures. Based on overlapping inhibitory mechanisms, many anticonvulsant compounds have been found to exhibit both analgesic and antiepileptic activities. An analgesic neuropeptide W (NPW) targets recently deorphanized G-protein coupled receptors. Here, we tested the hypothesis that the analgesic activity of NPW may lead to the discovery of its antiepileptic properties. Indeed, direct administration of NPW into the brain potently reduced seizures in mice. To confirm this discovery, we rationally designed, synthesized, and characterized NPW analogues that exhibited anticonvulsant activities following systemic administration. Our results suggest that the combination of neuropeptide repositioning and engineering NPW analogues that penetrate the blood-brain barrier could provide new drug leads, not only for the treatment of epilepsy and pain but also for studying effects of this peptide on regulating feeding and energy metabolism coupled to leptin levels in the brain.</dcterms:abstract>
        <bib:pages>51-56</bib:pages>
        <dc:date>2010-11-18</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400287/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22826747
PMCID: PMC3400287</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7995">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400287/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368646/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>6</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100010p</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Weeks</foaf:surname>
                        <foaf:givenname>Kathrine R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dwyer</foaf:surname>
                        <foaf:givenname>Donard S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Aamodt</foaf:surname>
                        <foaf:givenname>Eric J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6130"/>
        <dc:title>Antipsychotic Drugs Activate the C. elegans Akt Pathway via the DAF-2 Insulin/IGF-1 Receptor</dc:title>
        <dcterms:abstract>, The molecular modes of action of antipsychotic drugs are poorly understood beyond their effects at the dopamine D2 receptor. Previous studies have placed Akt signaling downstream of D2 dopamine receptors, and recent data have suggested an association between psychotic illnesses and defective Akt signaling. To characterize the effect of antipsychotic drugs on the Akt pathway, we used the model organism C. elegans, a simple system where the Akt/forkhead box O transcription factor (FOXO) pathway has been well characterized. All major classes of antipsychotic drugs increased signaling through the insulin/Akt/FOXO pathway, whereas four other drugs that are known to affect the central nervous system did not. The antipsychotic drugs inhibited dauer formation, dauer recovery, and shortened lifespan, three biological processes affected by Akt signaling. Genetic analysis showed that AKT-1 and the insulin and insulin-like growth factor receptor, DAF-2, were required for the antipsychotic drugs to increase signaling. Serotonin synthesis was partially involved, whereas the mitogen activated protein kinase (MAPK), SEK-1 is a MAP kinase kinase (MAPKK), and calcineurin were not involved. This is the first example of a common but specific molecular effect produced by all presently known antipsychotic drugs in any biological system. Because untreated schizophrenics have been reported to have low levels of Akt signaling, increased Akt signaling might contribute to the therapeutic actions of antipsychotic drugs.</dcterms:abstract>
        <bib:pages>463-473</bib:pages>
        <dc:date>2010-03-25</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368646/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778838
PMCID: PMC3368646</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6130">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368646/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369706/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100094b</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenname>Wei-Guang</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenname>Tian-Le</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6759"/>
        <dc:title>ASIC3 Channels in Multimodal Sensory Perception</dc:title>
        <dcterms:abstract>, Acid-sensing ion channels (ASICs), which are members of the sodium-selective cation channels belonging to the epithelial sodium channel/degenerin (ENaC/DEG) family, act as membrane-bound receptors for extracellular protons as well as nonproton ligands. At least five ASIC subunits have been identified in mammalian neurons, which form both homotrimeric and heterotrimeric channels. The highly proton sensitive ASIC3 channels are predominantly distributed in peripheral sensory neurons, correlating with their roles in multimodal sensory perception, including nociception, mechanosensation, and chemosensation. Different from other ASIC subunit composing ion channels, ASIC3 channels can mediate a sustained window current in response to mild extracellular acidosis (pH 7.3−6.7), which often occurs accompanied by many sensory stimuli. Furthermore, recent evidence indicates that the sustained component of ASIC3 currents can be enhanced by nonproton ligands including the endogenous metabolite agmatine. In this review, we first summarize the growing body of evidence for the involvement of ASIC3 channels in multimodal sensory perception and then discuss the potential mechanisms underlying ASIC3 activation and mediation of sensory perception, with a special emphasis on its role in nociception. We conclude that ASIC3 activation and modulation by diverse sensory stimuli represent a new avenue for understanding the role of ASIC3 channels in sensory perception. Furthermore, the emerging implications of ASIC3 channels in multiple sensory dysfunctions including nociception allow the development of new pharmacotherapy.</dcterms:abstract>
        <bib:pages>26-37</bib:pages>
        <dc:date>2010-11-12</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369706/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778854
PMCID: PMC3369706</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6759">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369706/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991071/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>9</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000183</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Barizuddin</foaf:surname>
                        <foaf:givenname>Syed</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenname>Xin</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mathai</foaf:surname>
                        <foaf:givenname>Joseph C.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hossain</foaf:surname>
                        <foaf:givenname>Maruf</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gillis</foaf:surname>
                        <foaf:givenname>Kevin, D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gangopadhyay</foaf:surname>
                        <foaf:givenname>Shubhra</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6413"/>
        <dc:title>Automated Targeting of Cells to Electrochemical Electrodes Using a Surface Chemistry Approach for the Measurement of Quantal Exocytosis</dc:title>
        <dcterms:abstract>, Here, we describe a method to fabricate a multichannel high-throughput microchip device for the measurement of quantal transmitter release from individual cells. Instead of bringing carbon-fiber electrodes to cells, the device uses a surface chemistry approach to bring cells to an array of electrochemical microelectrodes. The microelectrodes are small and cytophilic in order to promote adhesion of a single cell, whereas all other areas of the chip are covered with a thin cytophobic film to block cell attachement and facilitate the movement of cells to electrodes. This cytophobic film also insulates unused areas of the conductive film; thus, the alignment of cell docking sites to working electrodes is automatic. Amperometric spikes resulting from single-granule fusion events were recorded on the device and had amplitudes and kinetics similar to those measured using carbon-fiber microelectrodes. Use of this device will increase the pace of basic neuroscience research and may also find applications in drug discovery or validation.</dcterms:abstract>
        <bib:pages>590-597</bib:pages>
        <dc:date>2010-07-30</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991071/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21113333
PMCID: PMC2991071</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6413">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991071/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837340/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900014m</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Eckenhoff</foaf:surname>
                        <foaf:givenname>Roderic G.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xi</foaf:surname>
                        <foaf:givenname>Jin</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shimaoka</foaf:surname>
                        <foaf:givenname>Motomu</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bhattacharji</foaf:surname>
                        <foaf:givenname>Aditya</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Covarrubias</foaf:surname>
                        <foaf:givenname>Manuel</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dailey</foaf:surname>
                        <foaf:givenname>William P.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6663"/>
        <dc:title>Azi-isoflurane, a Photolabel Analog of the Commonly Used Inhaled General Anesthetic Isoflurane</dc:title>
        <dcterms:abstract>, Volatility and low-affinity hamper an ability to define molecular
targets of the inhaled anesthetics. Photolabels have proven to be
a useful approach in this regard, although none have closely mimicked
contemporary drugs. We report here the synthesis and validation of
azi-isoflurane, a compound constructed by adding a diazirinyl moiety
to the methyl carbon of the commonly used general anesthetic isoflurane.
Azi-isoflurane is slightly more hydrophobic than isoflurane, and more
potent in tadpoles. This novel compound inhibits Shaw2 K+ channel currents similarly to isoflurane and binds to apoferritin
with enhanced affinity. Finally, when irradiated at 300 nm, azi-isoflurane
adducts to residues known to line isoflurane-binding sites in apoferritin
and integrin LFA-1, the only proteins with isoflurane binding sites
defined by crystallography. This reagent should allow rapid discovery
of isoflurane molecular targets and binding sites within those targets.</dcterms:abstract>
        <bib:pages>139-145</bib:pages>
        <dc:date>2009-10-12</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837340/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20228895
PMCID: PMC2837340</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6663">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837340/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843923/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900012y</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Singh</foaf:surname>
                        <foaf:givenname>Yogesh S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sawarynski</foaf:surname>
                        <foaf:givenname>Lauren E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Michael</foaf:surname>
                        <foaf:givenname>Heather M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ferrell</foaf:surname>
                        <foaf:givenname>Robert E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Murphey-Corb</foaf:surname>
                        <foaf:givenname>Michael A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Swain</foaf:surname>
                        <foaf:givenname>Greg M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Patel</foaf:surname>
                        <foaf:givenname>Bhavik A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Andrews</foaf:surname>
                        <foaf:givenname>Anne M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9095"/>
        <dc:title>Boron-Doped Diamond Microelectrodes Reveal Reduced Serotonin Uptake Rates in Lymphocytes from Adult Rhesus Monkeys Carrying the Short Allele of the 5-HTTLPR</dc:title>
        <dcterms:abstract>, Uptake resolved by high-speed chronoamperometry on a second-by-second basis has revealed important differences in brain serotonin transporter function associated with genetic variability. Here, we use chronoamperometry to investigate variations in serotonin transport in primary lymphocytes associated with the rhesus serotonin transporter gene-linked polymorphism (rh5-HTTLPR), a promoter polymorphism whose orthologues occur only in higher order primates including humans. Serotonin clearance by lymphocytes is Na+-dependent and inhibited by the serotonin-selective reuptake inhibitor paroxetine (Paxil), indicative of active uptake by serotonin transporters. Moreover, reductions in serotonin uptake rates are evident in lymphocytes from monkeys with one or two copies of the short ‘s’ allele of the rh5-HTTLPR (s/s &lt; s/l &lt; l/l). These findings illustrate that rh5-HTTLPR-related alterations in serotonin uptake are present during adulthood in peripheral blood cells natively expressing serotonin transporters. Moreover, they suggest that lymphocytes can be used as peripheral biomarkers for investigating genetic or pharmacologic alterations in serotonin transporter function. Use of boron-doped diamond microelectrodes for measuring serotonin uptake, in contrast to carbon fiber microelectrodes used previously in the brain, enabled these high-sensitivity and high-resolution measurements. Boron-doped diamond microelectrodes show excellent signal-to-noise and signal-to-background ratios due mainly to low background currents and are highly resistant to fouling when exposed to lymphocytes or high concentrations of serotonin.</dcterms:abstract>
        <bib:pages>49-64</bib:pages>
        <dc:date>2009-11-16</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843923/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20352073
PMCID: PMC2843923</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9095">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843923/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873219/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100005p</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Murray</foaf:surname>
                        <foaf:givenname>Jennifer E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bevins</foaf:surname>
                        <foaf:givenname>Rick A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8023"/>
        <dc:title>Cannabinoid Conditioned Reward and Aversion: Behavioral and Neural Processes</dc:title>
        <dcterms:abstract>, The discovery that delta-9-tetrahydrocannabinol (Δ9-THC) is the primary psychoactive ingredient in marijuana prompted research that helped elucidate the endogenous cannabinoid system of the brain. Δ9-THC and other cannabinoid ligands with agonist action (CP 55,940, HU210, and WIN 55,212-2) increase firing of dopamine neurons and increase synaptic dopamine in brain regions associated with reward and drug addiction. Such changes in cellular processes have prompted investigators to examine the conditioned rewarding effects of the cannabinoid ligands using the place conditioning task with rats and mice. As reviewed here, these cannabinoid ligands can condition place preferences (evidence for rewarding effects) and place aversions (evidence for aversive qualities). Notably, the procedural details used in these place conditioning studies have varied across laboratories. Such variation includes differences in apparatus type, existence of procedural biases, dose, number of conditioning trials, injection-to-placement intervals, and pretraining drug exposure. Some differences in outcome across studies can be explained by these procedural variables. For example, low doses of Δ9-THC appear to have conditioned rewarding effects, whereas higher doses have aversive effects that either mask these rewarding effects or condition a place aversion. Throughout this review, we highlight key areas that need further research.</dcterms:abstract>
        <bib:pages>265-278</bib:pages>
        <dc:date>2010-03-10</dc:date>
        <z:shortTitle>Cannabinoid Conditioned Reward and Aversion</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873219/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20495676
PMCID: PMC2873219</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8023">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873219/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368661/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900042c</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bryant</foaf:surname>
                        <foaf:givenname>Bruce</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenname>Jiang</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Audige</foaf:surname>
                        <foaf:givenname>Valery</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lischka</foaf:surname>
                        <foaf:givenname>Fritz W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rawson</foaf:surname>
                        <foaf:givenname>Nancy E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8857"/>
        <dc:title>Cellular Basis for the Olfactory Response to Nicotine</dc:title>
        <dcterms:abstract>, Smokers regulate their smoking behavior on the basis of sensory stimuli independently of the pharmacological effects of nicotine (RoseJ. E., et al. (1993) Pharmacol., Biochem. Behav.44 (4), 891−9008469698). A better understanding of sensory mechanisms underlying smoking behavior may help to develop more effective smoking alternatives. Olfactory stimulation by nicotine makes up a considerable part of the flavor of tobacco smoke, yet our understanding of the cellular mechanisms responsible for olfactory detection of nicotine remains incomplete. We used biophysical methods to characterize the nicotine sensitivity and response mechanisms of neurons from olfactory epithelium. In view of substantial differences in the olfactory receptor repertoire between rodent and human (MombaertsP. (1999) Annu. Rev. Neurosci.22, 487−50910202546), we studied biopsied human olfactory sensory neurons (OSNs), cultured human olfactory cells (GomezG., et al. (2000) J. Neurosci. Res.62 (5), 737−74911104513), and rat olfactory neurons. Rat and human OSNs responded to S(−)-nicotine with a concentration dependent influx of calcium and activation of adenylate cyclase. Some rat OSNs displayed some stereoselectivity, with neurons responding to either enantiomer alone or to both. Freshly biopsied and primary cultured human olfactory neurons were less stereoselective. Nicotinic cholinergic antagonists had no effect on the responses of rat or human OSNs to nicotine. Patch clamp recording of rat OSNs revealed a nicotine-activated, calcium-sensitive nonspecific cation channel. These results indicate that nicotine activates a canonical olfactory receptor pathway rather than nicotinic cholinergic receptors on OSNs. Further, because the nicotine-sensitive mechanisms of rodents appear generally similar to those of humans, this animal model is an appropriate one for studies of nicotine sensation.</dcterms:abstract>
        <bib:pages>246-256</bib:pages>
        <dc:date>2010-02-26</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368661/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22777075
PMCID: PMC3368661</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8857">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368661/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077578/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000843</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lundstrom</foaf:surname>
                        <foaf:givenname>Johan N.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Boesveldt</foaf:surname>
                        <foaf:givenname>Sanne</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Albrecht</foaf:surname>
                        <foaf:givenname>Jessica</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8396"/>
        <dc:title>Central Processing of the Chemical Senses: An Overview</dc:title>
        <dcterms:abstract>, Our knowledge regarding the neural processing of the three chemical senses has been considerably lagging behind that of our other senses. It is only during the last 25 years that significant advances have been made in our understanding of where in the human brain odors, tastants, and trigeminal stimuli are processed. Here, we provide an overview of the current knowledge of how the human brain processes chemical stimuli based on findings in neuroimaging studies using positron emission tomography and functional magnetic resonance imaging. Additionally, we provide new insights from recent meta-analyses, on the basis of all published neuroimaging studies of the chemical senses, of where the chemical senses converge in the brain.</dcterms:abstract>
        <bib:pages>5-16</bib:pages>
        <dc:date>2010-11-16</dc:date>
        <z:shortTitle>Central Processing of the Chemical Senses</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077578/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21503268
PMCID: PMC3077578</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8396">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077578/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873204/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900046a</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kuai</foaf:surname>
                        <foaf:givenname>Letian</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenname>Xiang</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Madison</foaf:surname>
                        <foaf:givenname>Jon M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schreiber</foaf:surname>
                        <foaf:givenname>Stuart L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Scolnick</foaf:surname>
                        <foaf:givenname>Edward M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Haggarty</foaf:surname>
                        <foaf:givenname>Stephen J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9007"/>
        <dc:title>Chemical Genetics Identifies Small-Molecule Modulators of Neuritogenesis Involving Neuregulin-1/ErbB4 Signaling</dc:title>
        <dcterms:abstract>, Genetic findings have suggested that neuregulin-1 (Nrg1) and its receptor v-erb-a erythroblastic leukemia viral oncogene homologue 4 (ErbB4) may play a role in neuropsychiatric diseases. However, the downstream signaling events and relevant phenotypic consequences of altered Nrg1 signaling in the nervous system remain poorly understood. To identify small molecules for probing Nrg1−ErbB4 signaling, a PC12-cell model was developed and used to perform a live-cell, image-based screen of the effects of small molecules on Nrg1-induced neuritogenesis. By comparison of the resulting phenotypic data to that of a similar screening performed with nerve growth factor (NGF), this multidimensional screen identified compounds that directly inhibit Nrg1−ErbB4 signaling, such as the 4-anilino-quinazoline Iressa (gefitinib), as well as compounds that potentiate Nrg1−ErbB4 signaling, such as the indolocarbazole K-252a. These findings provide new insights into the regulation of Nrg1−ErbB4 signaling events and demonstrate the feasibility of using such a multidimensional, chemical-genetic approach for discovering probes of pathways implicated in neuropsychiatric diseases.</dcterms:abstract>
        <bib:pages>325-342</bib:pages>
        <dc:date>2010-01-28</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873204/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20495671
PMCID: PMC2873204</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9007">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873204/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369707/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100102c</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Viana</foaf:surname>
                        <foaf:givenname>Felix</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6154"/>
        <dc:title>Chemosensory Properties of the Trigeminal System</dc:title>
        <dcterms:abstract>, The capacity of cutaneous, including trigeminal endings, to detect chemicals is known as chemesthesis or cutaneous chemosensation. This sensory function involves the activation of nociceptor and thermoreceptor endings and has a protective or defensive function, as many of these substances are irritants or poisonous. However, humans have also developed a liking for the distinct sharpness or pungency of many foods, beverages, and spices following activation of the same sensory afferents. Our understanding of the cellular and molecular mechanisms of chemosensation in the trigeminal system has experienced enormous progress in the past decade, following the cloning and functional characterization of several ion channels activated by physical and chemical stimuli. This brief review attempts to summarize our current knowledge in this field, including a functional description of various sensory channels, especially TRP channels, involved in trigeminal chemosensitivy. Finally, some of these new findings are discussed in the context of the pathophysiology of trigeminal chemosensation, including pain, pruritus, migraine, cough, airway inflammation, and ophthalmic diseases.</dcterms:abstract>
        <bib:pages>38-50</bib:pages>
        <dc:date>2010-12-22</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369707/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778855
PMCID: PMC3369707</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6154">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369707/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847303/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900028s</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chen</foaf:surname>
                        <foaf:givenname>Ruibing</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hui</foaf:surname>
                        <foaf:givenname>Limei</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cape</foaf:surname>
                        <foaf:givenname>Stephanie S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenname>Junhua</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Li</foaf:surname>
                        <foaf:givenname>Lingjun</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8805"/>
        <dc:title>Comparative Neuropeptidomic Analysis of Food Intake via a Multifaceted Mass Spectrometric Approach</dc:title>
        <dcterms:abstract>, Feeding behavior is a fundamental aspect of energy homeostasis and is crucial for animal survival. This process is regulated by a multitude of neurotransmitters including neuropeptides within a complex neuroendocrine system. Given the high chemical complexity and wide distribution of neuropeptides, the precise molecular mechanisms at the cellular and network levels remain elusive. Here we report comparative neuropeptidomic analysis of brain and a major neuroendocrine organ in a crustacean model organism in response to feeding. A multifaceted approach employing direct tissue matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS), stable isotopic labeling of neuropeptide extracts for quantitation, and mass spectrometric imaging (MSI) has been employed to obtain complementary information on the expression changes of a large array of neuropeptides in the brain and the pericardial organ (PO) in the crab Cancer borealis. Multiple neuropeptides exhibited changes in abundance after feeding, including RFamides, Cancer borealis tachykinin-related peptides (CabTRPs), RYamides, and pyrokinins. By combining quantitative analysis of neuropeptide changes via isotopic labeling of brain extract and MSI mapping of neuropeptides of brain slices, we identified the boundary of the olfactory lobe (ON) and the median protocerebrum (MPC) area as two potential feeding centers in the crab brain.</dcterms:abstract>
        <bib:pages>204-214</bib:pages>
        <dc:date>2009-12-28</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847303/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20368756
PMCID: PMC2847303</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8805">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847303/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882315/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>5</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900033s</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenname>Jia</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Parsons</foaf:surname>
                        <foaf:givenname>Stanley M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7378"/>
        <dc:title>Conformational Propensities of Peptides Mimicking Transmembrane Helix 5 and Motif C in Wild-Type and Mutant Vesicular Acetylcholine Transporters</dc:title>
        <dcterms:abstract>, Vesicular acetylcholine transporter (VAChT) is a member of the major facilitator superfamily (MFS). It contains conserved sequence motifs originally defined in the bacterial multidrug resistance transporter family of the MFS. Motif C (GSLV227A228PPFGGIL) is located at the C-terminal end of transmembrane helix 5 (TM 5) in VAChT. The motif is rich in glycine and proline residues that often have special roles in backbone conformations of TMs. The A228G mutant of VAChT transports >3-fold faster than wild-type does [Chandrasekaran et al. (2006) J. Neurochem.98, 1551−1559.16923166]. In the current study, the structure of Loop 4/5, TM 5, and motif C were taken from a three-dimensional homology model for human VAChT. The peptide was immersed in implicit membrane and energy-minimized, and molecular dynamics (MD) were simulated. Kinking and wobbling occur in otherwise helical peptide at the hinge residues L226 and V227. MD also were simulated for A228G single mutant and V227L−A228A double mutant peptides to investigate the structural roles of the A228G mutation and β-branching at V227. Mutant peptides exhibit increased wobbling at the hinge residues, but in the double mutant the increase is less. Because motif C participates in the interface that mediates hypothesized rocker-switch reorientation of the acetylcholine binding site during transport, dynamics in motif C might be an important contributor to transport rate.</dcterms:abstract>
        <bib:pages>381-390</bib:pages>
        <dc:date>2010-01-29</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882315/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20544010
PMCID: PMC2882315</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7378">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882315/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369730/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100090g</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pottie</foaf:surname>
                        <foaf:givenname>Ian R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Higgins</foaf:surname>
                        <foaf:givenname>Emma A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Blackman</foaf:surname>
                        <foaf:givenname>Rachelle A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Macdonald</foaf:surname>
                        <foaf:givenname>Ian R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Martin</foaf:surname>
                        <foaf:givenname>Earl</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Darvesh</foaf:surname>
                        <foaf:givenname>Sultan</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7673"/>
        <dc:title>Cysteine Thioesters as Myelin Proteolipid Protein Analogues to Examine the Role of Butyrylcholinesterase in Myelin Decompaction</dc:title>
        <dcterms:abstract>, Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disorder involving demyelination, axonal transection, and neuronal loss in the brain. Recent studies have indicated that active MS lesions express elevated levels of butyrylcholinesterase (BuChE). BuChE can hydrolyze a wide variety of esters, including fatty acid esters of protein. Proteolipid protein (PLP), an important transmembrane protein component of myelin, has six cysteine residues acylated, via thioester linkages, with fatty acids, usually palmitic, that contribute to the stability of myelin. Experimental chemical deacylation of PLP has been shown to lead to decompaction of myelin. Because of elevated levels of BuChE in active MS lesions and its propensity to catalyze the hydrolysis of acylated protein, we hypothesized that this enzyme may contribute to deacylation of PLP in MS, leading to decompaction of myelin and contributing to demyelination. To test this hypothesis, a series of increasing chain length (C2−C16) acyl thioester derivatives of N-acetyl-l-cysteine methyl ester were synthesized and examined for hydrolysis by human cholinesterases. All N-acetyl-l-cysteine fatty acyl thioester derivatives were hydrolyzed by BuChE but not by the related enzyme acetylcholinesterase. In addition, it was observed that the affinity of BuChE for the compound increased the longer the fatty acid chain, with the highest affinity for cysteine bound to palmitic acid. This suggests that the elevated levels of BuChE observed in active MS lesions could be related to the decompaction of myelin characteristic of the disorder.</dcterms:abstract>
        <bib:pages>151-159</bib:pages>
        <dc:date>2010-12-30</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369730/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778864
PMCID: PMC3369730</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7673">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369730/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368653/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>6</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100007x</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wager</foaf:surname>
                        <foaf:givenname>Travis T.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chandrasekaran</foaf:surname>
                        <foaf:givenname>Ramalakshmi Y.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hou</foaf:surname>
                        <foaf:givenname>Xinjun</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Troutman</foaf:surname>
                        <foaf:givenname>Matthew D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Verhoest</foaf:surname>
                        <foaf:givenname>Patrick R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Villalobos</foaf:surname>
                        <foaf:givenname>Anabella</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Will</foaf:surname>
                        <foaf:givenname>Yvonne</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6260"/>
        <dc:title>Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes</dc:title>
        <dcterms:abstract>, As part of our effort to increase survival of drug candidates and to move our medicinal chemistry design to higher probability space for success in the Neuroscience therapeutic area, we embarked on a detailed study of the property space for a collection of central nervous system (CNS) molecules. We carried out a thorough analysis of properties for 119 marketed CNS drugs and a set of 108 Pfizer CNS candidates. In particular, we focused on understanding the relationships between physicochemical properties, in vitro ADME (absorption, distribution, metabolism, and elimination) attributes, primary pharmacology binding efficiencies, and in vitro safety data for these two sets of compounds. This scholarship provides guidance for the design of CNS molecules in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.</dcterms:abstract>
        <bib:pages>420-434</bib:pages>
        <dc:date>2010-03-25</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368653/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778836
PMCID: PMC3368653</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6260">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368653/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368673/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>5</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100001j</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shechter</foaf:surname>
                        <foaf:givenname>Yoram</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heldman</foaf:surname>
                        <foaf:givenname>Eli</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sasson</foaf:surname>
                        <foaf:givenname>Keren</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bachar</foaf:surname>
                        <foaf:givenname>Tzach</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Popov</foaf:surname>
                        <foaf:givenname>Mary</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fridkin</foaf:surname>
                        <foaf:givenname>Matityahu</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7447"/>
        <dc:title>Delivery of Neuropeptides from the Periphery to the Brain: Studies with Enkephalin</dc:title>
        <dcterms:abstract>, Many peptides with the potential of therapeutic action for brain disorders are not in clinical use because they are unable to cross the blood−brain barrier (BBB) following peripheral administration. We have developed two potential strategies for the delivery of peptides to the brain and demonstrated their feasibility with enkephalins. In the first approach, designated induced reversible lipophilization, Leu/Met Enkephalins were converted to 9-fluorenylmethoxycarbonyl (Fmoc) derived lipophilic prodrug analogues, which undergo slow, spontaneous hydrolysis under physiological conditions, generating the native agonists. In contrast to Enkephalin, Fmoc-Met-Enkephalin was found to facilitate an analgesic effect following intraperitoneal administration in mice. Fmoc-Leu-Enkephalin was not analgesic. In the second approach, Enkephalin was linked to BBB transport vectors through an Fmoc based linker spacer, forming conjugates that slowly release Enkephalin under physiological conditions. A pronounced antinociceptive response was thus obtained following intraperitoneal administration of either cationized-human serum albumin-Fmoc-Enkephalin or polyethylene glycol5-Fmoc-Enkephalin. Derivatives of Enkephalin covalently linked to the same BBB-transport vectors through a stable (nonreversible) chemical bond were not analgesic. In summary, we have demonstrated that lipophilicity can be conferred to hydrophilic peptides to a degree permitting the permeation of the BBB by passive diffusion, without the drawback of agonist inactivation, which is often caused by irreversible derivatization. Similarly, in the second strategy, the conjugation to BBB-permeable vectors overcomes the obstacle of peptide inactivation by releasing the active form in the central nervous system.</dcterms:abstract>
        <bib:pages>399-406</bib:pages>
        <dc:date>2010-02-16</dc:date>
        <z:shortTitle>Delivery of Neuropeptides from the Periphery to the Brain</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368673/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778833
PMCID: PMC3368673</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7447">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368673/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082957/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100089b</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wang</foaf:surname>
                        <foaf:givenname>Yuying</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Park</foaf:surname>
                        <foaf:givenname>Ki Duk</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Salome</foaf:surname>
                        <foaf:givenname>Christophe</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wilson</foaf:surname>
                        <foaf:givenname>Sarah M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Stables</foaf:surname>
                        <foaf:givenname>James P.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenname>Rihe</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Khanna</foaf:surname>
                        <foaf:givenname>Rajesh</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kohn</foaf:surname>
                        <foaf:givenname>Harold</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6089"/>
        <dc:title>Development and Characterization of Novel Derivatives of the Antiepileptic Drug Lacosamide That Exhibit Far Greater Enhancement in Slow Inactivation of Voltage-Gated Sodium Channels</dc:title>
        <dcterms:abstract>, The novel antiepileptic drug (R)-N-benzyl 2-acetamido-3-methoxypropionamide ((R)-lacosamide, Vimpat ((R)-1)) was recently approved in the United States and Europe for adjuvant treatment of partial-onset seizures in adults. (R)-1 preferentially enhances slow inactivation of voltage-gated Na+ currents, a pharmacological process relevant in the hyperexcitable neuron. We have advanced a strategy to identify lacosamide binding partners by attaching affinity bait (AB) and chemical reporter (CR) groups to (R)-1 to aid receptor detection and isolation. We showed that select lacosamide AB and AB&amp;CR derivatives exhibited excellent activities similar to (R)-1 in the maximal electroshock seizure model in rodents. Here, we examined the effect of these lacosamide AB and AB&amp;CR derivatives and compared them with (R)-1 on Na+ channel function in central nervous system (CNS) catecholaminergic (CAD) cells. Using whole-cell patch clamp electrophysiology, we demonstrated that the test compounds do not affect the Na+ channel fast inactivation process, that they were far better modulators of slow inactivation than (R)-1, and that modulation of the slow inactivation process was stereospecific. The lacosamide AB agents that contained either an electrophilic isothiocyanate ((R)-5) or a photolabile azide ((R)-8) unit upon AB activation gave modest levels of permanent Na+ channel slow inactivation, providing initial evidence that these compounds may have covalently reacted with their cognate receptor(s). Our findings support the further use of these agents to delineate the (R)-1-mediated Na+ channel slow inactivation process.</dcterms:abstract>
        <bib:pages>90-106</bib:pages>
        <dc:date>2010-11-24</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082957/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21532923
PMCID: PMC3082957</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6089">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082957/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936488/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>8</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100011e</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Davis</foaf:surname>
                        <foaf:givenname>Albert A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heilman</foaf:surname>
                        <foaf:givenname>Craig J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brady</foaf:surname>
                        <foaf:givenname>Ashley E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Miller</foaf:surname>
                        <foaf:givenname>Nicole R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fuerstenau-Sharp</foaf:surname>
                        <foaf:givenname>Maya</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hanson</foaf:surname>
                        <foaf:givenname>Bonnie J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Conn</foaf:surname>
                        <foaf:givenname>P. Jeffrey</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lah</foaf:surname>
                        <foaf:givenname>James J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Levey</foaf:surname>
                        <foaf:givenname>Allan I.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7449"/>
        <dc:title>Differential Effects of Allosteric M1 Muscarinic Acetylcholine Receptor Agonists on Receptor Activation, Arrestin 3 Recruitment, and Receptor Downregulation</dc:title>
        <dcterms:abstract>, Muscarinic acetylcholine receptors (mAChRs) are drug targets for multiple neurodegenerative and neuropsychiatric disorders, but the full therapeutic potential of mAChR-targeted drugs has not been realized, mainly because of a lack of subtype-selective agonists. Recent advances have allowed the development of highly selective agonists that bind to an allosteric site on the M1 mAChR that is spatially distinct from the orthosteric acetylcholine binding site, but less is known about the profile of intracellular signals activated by orthosteric versus allosteric M1 mAChR agonists. We investigated the activation and regulatory mechanisms of two structurally distinct allosteric M1 mAChR agonists, AC260584 and TBPB. We show that allosteric agonists potently activate multiple signal transduction pathways linked to the M1 mAChR receptor but, compared to orthosteric agonists, much less efficiently recruit arrestin 3, a protein involved in the regulation of G-protein coupled receptor signaling. Consistent with decreased arrestin recruitment, both allosteric agonists showed blunted responses in measurements of receptor desensitization, internalization, and downregulation. These results advance the understanding of mAChR biology and may shed light on unanticipated differences in the pharmacology of orthosteric versus allosteric agonists that might be capitalized upon for drug development for the treatment of CNS diseases.</dcterms:abstract>
        <bib:pages>542-551</bib:pages>
        <dc:date>2010-06-10</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936488/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20835371
PMCID: PMC2936488</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7449">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936488/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855151/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn9000022</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Millet</foaf:surname>
                        <foaf:givenname>Larry J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bora</foaf:surname>
                        <foaf:givenname>Adriana</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sweedler</foaf:surname>
                        <foaf:givenname>Jonathan V.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gillette</foaf:surname>
                        <foaf:givenname>Martha U.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8818"/>
        <dc:title>Direct Cellular Peptidomics of Supraoptic Magnocellular and Hippocampal Neurons in Low-Density Cocultures</dc:title>
        <dcterms:abstract>, Genomic and proteomic studies of brain regions of specialized function provide evidence that communication among neurons is mediated by systems of diverse chemical messengers. These analyses are largely tissue- or population-based, whereas the actual communication is from cell-to-cell. To understand the complement of intercellular signals produced by individual neurons, new methods are required. We have developed a novel neuron-to-neuron, serum-free coculture approach that was used to determine the higher-level cellular peptidome of individual primary mammalian neurons. We isolated magnocellular neurons from the supraoptic nucleus of early postnatal rat and maintained them in serum-free low-density cultures without glial support layers; under these conditions, they required low-density cocultured neurons. Coculturing magnocellular neurons with hippocampal neurons permitted local access to individual neurons within the culture for mass spectrometry. Using direct sampling, we obtained peptide profiles for spatially distinct, identifiable neurons within the coculture. We repeatedly detected 10 peaks that we assign to previously characterized peptides and 17 peaks that remain unassigned. Peptides from the vasopressin prohormone and secretogranin-2 are attributed to magnocellular neurons, whereas neurokinin A, peptide J, and neurokinin B are attributed to cultured hippocampal neurons. This approach enables the elucidation of cell-specific prohormone processing and the discovery of cell−cell signaling peptides.</dcterms:abstract>
        <bib:pages>36-48</bib:pages>
        <dc:date>2009-10-14</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855151/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20401326
PMCID: PMC2855151</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8818">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855151/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180826/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900003h</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lebois</foaf:surname>
                        <foaf:givenname>Evan P</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bridges</foaf:surname>
                        <foaf:givenname>Thomas
M</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lewis</foaf:surname>
                        <foaf:givenname>L. Michelle</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dawson</foaf:surname>
                        <foaf:givenname>Eric S</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kane</foaf:surname>
                        <foaf:givenname>Alexander S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xiang</foaf:surname>
                        <foaf:givenname>Zixiu</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jadhav</foaf:surname>
                        <foaf:givenname>Satyawan B</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yin</foaf:surname>
                        <foaf:givenname>Huiyong</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kennedy</foaf:surname>
                        <foaf:givenname>J. Phillip</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Meiler</foaf:surname>
                        <foaf:givenname>Jens</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Niswender</foaf:surname>
                        <foaf:givenname>Colleen M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jones</foaf:surname>
                        <foaf:givenname>Carrie
K</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Conn</foaf:surname>
                        <foaf:givenname>P Jeffrey</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Weaver</foaf:surname>
                        <foaf:givenname>C David</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6049"/>
        <dc:title>Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M1 Receptor Function in the Central Nervous System</dc:title>
        <dcterms:abstract>, Cholinergic transmission in the forebrain is mediated primarily
by five subtypes of muscarinic acetylcholine receptors (mAChRs), termed
M1−M5. Of the mAChR subtypes, M1 is among the most heavily expressed in regions that are critical
for learning and memory and has been viewed as the most critical mAChR
subtype for memory and attention mechanisms. Unfortunately, it has
been difficult to develop selective activators of M1 and
other individual mAChR subtypes, which has prevented detailed studies
of the functional roles of selective activation of M1.
Using a functional high-throughput screening and subsequent diversity-oriented
synthesis approach, we have discovered a novel series of highly selective
M1 allosteric agonists. These compounds activate M1 with EC50 values in the 150−500 nM range
and have unprecedented, clean ancillary pharmacology (no substantial
activity at 10 μM across a large panel of targets). Targeted
mutagenesis revealed a potentially novel allosteric binding site in
the third extracellular loop of the M1 receptor for these
allosteric agonists. Optimized compounds, such as VU0357017, provide
excellent brain exposure after systemic dosing and have robust in vivo efficacy in reversing scopolamine-induced deficits
in a rodent model of contextual fear conditioning. This series of
selective M1 allosteric agonists provides critical research
tools to allow dissection of M1-mediated effects in the
CNS and potential leads for novel treatments for Alzheimer’s
disease and schizophrenia.</dcterms:abstract>
        <bib:pages>104-121</bib:pages>
        <dc:date>2009-09-25</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180826/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21961051
PMCID: PMC3180826</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6049">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180826/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368638/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>12</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000638</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cid</foaf:surname>
                        <foaf:givenname>Jose Maria</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Duvey</foaf:surname>
                        <foaf:givenname>Guillaume</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cluzeau</foaf:surname>
                        <foaf:givenname>Philippe</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nhem</foaf:surname>
                        <foaf:givenname>Vanthea</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Macary</foaf:surname>
                        <foaf:givenname>Karim</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Raux</foaf:surname>
                        <foaf:givenname>Alexandre</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Poirier</foaf:surname>
                        <foaf:givenname>Nicolas</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Muller</foaf:surname>
                        <foaf:givenname>Jessica</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bolea</foaf:surname>
                        <foaf:givenname>Christelle</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Finn</foaf:surname>
                        <foaf:givenname>Terry</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Poli</foaf:surname>
                        <foaf:givenname>Sonia</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Epping-Jordan</foaf:surname>
                        <foaf:givenname>Mark</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chamelot</foaf:surname>
                        <foaf:givenname>Emilie</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Derouet</foaf:surname>
                        <foaf:givenname>Francis</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Girard</foaf:surname>
                        <foaf:givenname>Francoise</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Macdonald</foaf:surname>
                        <foaf:givenname>Gregor J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vega</foaf:surname>
                        <foaf:givenname>Juan Antonio</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>de Lucas</foaf:surname>
                        <foaf:givenname>Ana Isabel</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Matesanz</foaf:surname>
                        <foaf:givenname>Encarnacion</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lavreysen</foaf:surname>
                        <foaf:givenname>Hilde</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Linares</foaf:surname>
                        <foaf:givenname>Maria Lourdes</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Oehlrich</foaf:surname>
                        <foaf:givenname>Daniel</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Oyarzabal</foaf:surname>
                        <foaf:givenname>Julen</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tresadern</foaf:surname>
                        <foaf:givenname>Gary</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Trabanco</foaf:surname>
                        <foaf:givenname>Andres A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Andres</foaf:surname>
                        <foaf:givenname>Jose Ignacio</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Le Poul</foaf:surname>
                        <foaf:givenname>Emmanuel</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Imogai</foaf:surname>
                        <foaf:givenname>Hassan</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lutjens</foaf:surname>
                        <foaf:givenname>Robert</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rocher</foaf:surname>
                        <foaf:givenname>Jean-Philippe</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8728"/>
        <dc:title>Discovery of 1,5-Disubstituted Pyridones: A New Class of Positive Allosteric Modulators of the Metabotropic Glutamate 2 Receptor</dc:title>
        <dcterms:abstract>, A series of 1,5-disubstituted pyridones was identified as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 2 (mGluR2) via high throughput screening (HTS). Subsequent SAR exploration led to the identification of several compounds with improved in vitro activity. Lead compound 8 was further profiled and found to attenuate the increase in PCP induced locomotor activity in mice.</dcterms:abstract>
        <bib:pages>788-795</bib:pages>
        <dc:date>2010-08-23</dc:date>
        <z:shortTitle>Discovery of 1,5-Disubstituted Pyridones</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368638/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778815
PMCID: PMC3368638</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8728">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368638/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369726/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100093f</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Larsen</foaf:surname>
                        <foaf:givenname>Ann M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Venskutonyte</foaf:surname>
                        <foaf:givenname>Raminta</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Valades</foaf:surname>
                        <foaf:givenname>Elena Anton</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nielsen</foaf:surname>
                        <foaf:givenname>Birgitte</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pickering</foaf:surname>
                        <foaf:givenname>Darryl S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bunch</foaf:surname>
                        <foaf:givenname>Lennart</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7756"/>
        <dc:title>Discovery of a New Class of Ionotropic Glutamate Receptor Antagonists by the Rational Design of (2S,3R)-3-(3-Carboxyphenyl)-pyrrolidine-2-carboxylic Acid</dc:title>
        <dcterms:abstract>, The kainic acid (KA) receptors belong to the class of glutamate (Glu) receptors in the brain and constitute a promising target for the treatment of neurological and/or psychiatric diseases such as schizophrenia, major depression, and epilepsy. Five KA subtypes have been identified and named GluK1−5. In this article, we present the discovery of (2S,3R)-3-(3-carboxyphenyl)-pyrrolidine-2-carboxylic acid (1) based on a rational design process. Target compound 1 was synthesized by a stereoselective strategy in 10 steps from commercially available starting materials. Binding affinities of 1 at native ionotropic Glu receptors were determined to be in the micromolar range (AMPA, 51 μM; KA, 22 μM; NMDA 6 μM), with the highest affinity for cloned homomeric KA receptor subtypes GluK1,3 (3.0 and 8.1 μM, respectively). Functional characterization of 1 by two electrode voltage clamp (TEVC) electrophysiology at a nondesensitizing mutant of GluK1 showed full competitive antagonistic behavior with a Kb of 11.4 μM.</dcterms:abstract>
        <bib:pages>107-114</bib:pages>
        <dc:date>2010-11-12</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369726/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778860
PMCID: PMC3369726</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7756">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369726/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957851/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>10</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100051m</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hammond</foaf:surname>
                        <foaf:givenname>Alexis S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rodriguez</foaf:surname>
                        <foaf:givenname>Alice L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Townsend</foaf:surname>
                        <foaf:givenname>Steven D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Niswender</foaf:surname>
                        <foaf:givenname>Colleen M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gregory</foaf:surname>
                        <foaf:givenname>Karen J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Conn</foaf:surname>
                        <foaf:givenname>P. Jeffrey</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7507"/>
        <dc:title>Discovery of a Novel Chemical Class of mGlu5 Allosteric Ligands with Distinct Modes of Pharmacology</dc:title>
        <dcterms:abstract>, We previously discovered a positive allosteric modulator (PAM) of the metabotropic glutamate receptor subtype 5 (mGlu5) termed 4 N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) that elicits receptor activation through a novel allosteric site on mGlu5, distinct from the classical mGlu5 negative allosteric modulator (NAM) MPEP allosteric site. However, a shallow structure−activity relationship (SAR), poor physiochemical properties, and weak PAM activity at rat mGlu5 limited the utility of CPPHA to explore allosteric activation of mGlu5 at a non-MPEP site. Thus, we performed a functional high-throughput screen (HTS) and identified a novel mGlu5 PAM benzamide scaffold, exemplified by VU0001850 (EC50 = 1.3 μM, 106% Glumax) and VU0040237 (EC50 = 350 nM, 84% Glu Max). An iterative parallel synthesis approach delivered 22 analogues, optimized mGlu5 PAM activity to afford VU0357121 (EC50 = 33 nM, 92% Glumax), and also revealed the first non-MPEP site neutral allosteric ligand (VU0365396). Like CPPHA, PAMs within this class do not appear to bind at the MPEP allosteric site based on radioligand binding studies. Moreover, mutagenesis studies indicate that VU0357121 and related analogues bind to a yet uncharacterized allosteric site on mGlu5, distinct from CPPHA, yet share a functional interaction with the MPEP site.</dcterms:abstract>
        <bib:pages>702-716</bib:pages>
        <dc:date>2010-08-19</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957851/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20981342
PMCID: PMC2957851</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7507">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957851/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992329/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>10</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100032f</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fulks</foaf:surname>
                        <foaf:givenname>Jenny L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>O'Bryhim</foaf:surname>
                        <foaf:givenname>Bliss E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wenzel</foaf:surname>
                        <foaf:givenname>Sara K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fowler</foaf:surname>
                        <foaf:givenname>Stephen C.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vorontsova</foaf:surname>
                        <foaf:givenname>Elena</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pinkston</foaf:surname>
                        <foaf:givenname>Jonathan W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ortiz</foaf:surname>
                        <foaf:givenname>Andrea N.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Johnson</foaf:surname>
                        <foaf:givenname>Michael A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9024"/>
        <dc:title>Dopamine Release and Uptake Impairments and Behavioral Alterations Observed in Mice that Model Fragile X Mental Retardation Syndrome</dc:title>
        <dcterms:abstract>, In this study, we evaluated the relationship between amphetamine-induced behavioral alterations and dopamine release and uptake characteristics in Fmr1 knockout (Fmr1 KO) mice, which model fragile X syndrome. The behavioral analyses, obtained at millisecond temporal resolution and 2 mm spatial resolution using a force-plate actometer, revealed that Fmr1 KO mice express a lower degree of focused stereotypy compared with wild-type (WT) control mice after injection with 10 mg/kg (ip) amphetamine. To identify potentially related neurochemical mechanisms underlying this phenomenon, we measured electrically evoked dopamine release and uptake using fast-scan cyclic voltammetry at carbon-fiber microelectrodes in striatal brain slices. At 10 weeks of age, dopamine release per pulse, which is dopamine release corrected for differences in uptake, was unchanged. However, at 15 (the age of behavioral testing) and 20 weeks of age, dopamine per pulse and the maximum rate of dopamine uptake was diminished in Fmr1 KO mice compared with WT mice. Dopamine uptake measurements, obtained at different amphetamine concentrations, indicated that dopamine transporters in both genotypes have equal affinities for amphetamine. Moreover, dopamine release measurements from slices treated with quinpirole, a D2-family receptor agonist, rule out enhanced D2 autoreceptor sensitivity as a mechanism of release inhibition. However, dopamine release, uncorrected for uptake and normalized against the corresponding predrug release peaks, increased in Fmr1 KO mice, but not in WT mice. Collectively, these data are consistent with a scenario in which a decrease in extracellular dopamine levels in the striatum result in diminished expression of focused stereotypy in Fmr1 KO mice.</dcterms:abstract>
        <bib:pages>679-690</bib:pages>
        <dc:date>2010-08-03</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992329/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21116467
PMCID: PMC2992329</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9024">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992329/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368671/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900027u</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cabaleiro-Lago</foaf:surname>
                        <foaf:givenname>Celia</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Quinlan-Pluck</foaf:surname>
                        <foaf:givenname>Fiona</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lynch</foaf:surname>
                        <foaf:givenname>Iseult</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dawson</foaf:surname>
                        <foaf:givenname>Kenneth A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Linse</foaf:surname>
                        <foaf:givenname>Sara</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6697"/>
        <dc:title>Dual Effect of Amino Modified Polystyrene Nanoparticles on Amyloid ? Protein Fibrillation</dc:title>
        <dcterms:abstract>, The fibrillation kinetics of the amyloid β peptide is analyzed in presence of cationic polystyrene nanoparticles of different size. The results highlight the importance of the ratio between the peptide and particle concentration. Depending on the specific ratio, the kinetic effects vary from acceleration of the fibrillation process by reducing the lag phase at low particle surface area in solution to inhibition of the fibrillation process at high particle surface area. The kinetic behavior can be explained if we assume a balance between two different pathways: first fibrillation of free monomer in solution and second nucleation and fibrillation promoted at the particle surface. The overall rate of fibrillation will depend on the interplay between these two pathways, and the predominance of one mechanism over the other will be determined by the relative equilibrium and rate constants.</dcterms:abstract>
        <bib:pages>279-287</bib:pages>
        <dc:date>2010-01-27</dc:date>
        <z:shortTitle>Dual Effect of Amino Modified Polystyrene Nanoparticles on Amyloid ?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368671/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778827
PMCID: PMC3368671</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6697">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368671/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368630/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn9000439</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_7908"/>
        <dc:title>Editorial</dc:title>
        <bib:pages>1</bib:pages>
        <dc:date>2010-01-05</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368630/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368630</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7908">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368630/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880810/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900024r</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Seidler</foaf:surname>
                        <foaf:givenname>Emily A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lieven</foaf:surname>
                        <foaf:givenname>Christopher J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Thompson</foaf:surname>
                        <foaf:givenname>Alex F.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Levin</foaf:surname>
                        <foaf:givenname>Leonard A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8527"/>
        <dc:title>Effectiveness of Novel Borane-Phosphine Complexes in Inhibiting Cell Death Depends on the Source of Superoxide Production Induced by Blockade of Mitochondrial Electron Transport</dc:title>
        <dcterms:abstract>, Central neurons undergo cell death after axotomy. One of the signaling pathways for this process is oxidative modification of one or more critical sulfhydryls in association with superoxide generation within mitochondria. Agents that reduce oxidized sulfhydryls are neuroprotective of axotomized retinal ganglion cells, and we hypothesized that this occurs via reversal of the effects of mitochondrial-produced superoxide. To study this, we measured the ability of the novel borane−phosphine complex drugs bis(3-propionic acid methyl ester)phenylphosphine borane complex (PB1) and (3-propionic acid methyl ester)diphenylphosphine borane complex (PB2) to inhibit the death of neuron-like RGC-5 cells induced by perturbation of the mitochondrial electron transport chain. We found that borane−phosphine complexes prevent neuronal cell death from superoxide produced by the redox-cycling agent menadione and the complex III inhibitor antimycin A, which produce superoxide toward the cytoplasm and matrix, but not the complex I inhibitor rotenone, which produces superoxide in the matrix alone. The ability of these disulfide reductants to prevent cell death may be predicted by the topology of superoxide production with respect to the mitochondrial matrix and extramitochondrial space.</dcterms:abstract>
        <bib:pages>95-103</bib:pages>
        <dc:date>2009-11-17</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880810/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20532184
PMCID: PMC2880810</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8527">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880810/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368672/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900041x</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pratim Bose</foaf:surname>
                        <foaf:givenname>Partha</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chatterjee</foaf:surname>
                        <foaf:givenname>Urmimala</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xie</foaf:surname>
                        <foaf:givenname>Ling</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Johansson</foaf:surname>
                        <foaf:givenname>Jan</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gothelid</foaf:surname>
                        <foaf:givenname>Emmanuelle</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Arvidsson</foaf:surname>
                        <foaf:givenname>Per I</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6492"/>
        <dc:title>Effects of Congo Red on A?1−40 Fibril Formation Process and Morphology</dc:title>
        <dcterms:abstract>, Alzheimer’s disease (AD), an age-related neurodegenerative disorder, is the most common form of dementia, and the seventh-leading cause of death in the United States. Current treatments offer only symptomatic relief; thus, there is a great need for new treatments with disease-modifying potential. One pathological hallmark of AD is so-called senile plaques, mainly made up of β-sheet-rich assemblies of 40- or 42-residue amyloid β-peptides (Aβ). Hence, inhibition of Aβ aggregation is actively explored as an option to prevent or treat AD. Congo red (CR) has been widely used as a model antiamyloid agent to prevent Aβ aggregation. Herein, we report detailed morphological studies on the effect of CR as an antiamyloid agent, by circular dichroism spectroscopy, photo-induced cross-linking reactions, and atomic force microscopy. We also demonstrate the effect of CR on a preaggregated sample of Aβ1−40. Our result suggests that Aβ1−40 follows a different path for aggregation in the presence of CR.</dcterms:abstract>
        <bib:pages>315-324</bib:pages>
        <dc:date>2010-02-03</dc:date>
        <z:shortTitle>Effects of Congo Red on A?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368672/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778828
PMCID: PMC3368672</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6492">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368672/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368634/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>10</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900019r</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bett</foaf:surname>
                        <foaf:givenname>Cyrus K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Serem</foaf:surname>
                        <foaf:givenname>Wilson K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fontenot</foaf:surname>
                        <foaf:givenname>Krystal R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hammer</foaf:surname>
                        <foaf:givenname>Robert P.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Garno</foaf:surname>
                        <foaf:givenname>Jayne C.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7989"/>
        <dc:title>Effects of Peptides Derived from Terminal Modifications of the A? Central Hydrophobic Core on A? Fibrillization</dc:title>
        <dcterms:abstract>, Considerable research effort has focused on the discovery of mitigators that block the toxicity of the β-amyloid peptide (Aβ) by targeting a specific step involved in Aβ fibrillogenesis and subsequent aggregation. Given that aggregation intermediates are hypothesized to be responsible for Aβ toxicity, such compounds could likely prevent or mitigate aggregation, or alternatively cause further association of toxic oligomers into larger nontoxic aggregates. Herein we investigate the effect of modifications of the KLVFF hydrophobic core of Aβ by replacing N- and C-terminal groups with various polar moieties. Several of these terminal modifications were found to disrupt the formation of amyloid fibrils and in some cases induced the disassembly of preformed fibrils. Significantly, mitigators that incorporate MiniPEG polar groups were found to be effective against Aβ1−40 fibrilligonesis. Previously, we have shown that mitigators incorporating alpha,alpha-disubstituted amino acids (ααAAs) were effective in disrupting fibril formation as well as inducing fibril disassembly. In this work, we further disclose that the number of polar residues (six) and ααAAs (three) in the original mitigator can be reduced without dramatically changing the ability to disrupt Aβ1−40 fibrillization in vitro.</dcterms:abstract>
        <bib:pages>661-678</bib:pages>
        <dc:date>2010-08-26</dc:date>
        <z:shortTitle>Effects of Peptides Derived from Terminal Modifications of the A?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368634/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778807
PMCID: PMC3368634</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7989">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368634/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368624/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900001b</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tschammer</foaf:surname>
                        <foaf:givenname>Nuska</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dorfler</foaf:surname>
                        <foaf:givenname>Miriam</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hubner</foaf:surname>
                        <foaf:givenname>Harald</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gmeiner</foaf:surname>
                        <foaf:givenname>Peter</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9245"/>
        <dc:title>Engineering a GPCR-Ligand Pair That Simulates the Activation of D2L by Dopamine</dc:title>
        <dcterms:abstract>, In the past decade, engineered G-protein-coupled receptors activated
solely by synthetic ligands (RASSLs) have been implemented as a new
means to study neurotransmission, which is controlled by G-protein-coupled
receptors in vitro and in vivo.
In this study, we report an engineered dopamine receptor D2L F3906.52W, which is the first identified RASSL for the
dopamine receptor family. The mutant receptor is characterized by
a disrupted ligand binding and complete loss of efficacy for the endogenous
ligand, dopamine, which is putatively due to a sterically induced
perturbation of H-bonding with conserved serine residues in TM5. Based
on this model, we rationally developed an aminoindane-derived set
of agonists. Because these agonists forgo analogous H-bonding functionalities,
their binding energy does not depend on the respective interactions.
Binding affinity and potency were optimized by ligand modifications
bearing molecular appendages that obviously interact with a secondary
recognition site provided by four hydrophobic residues in TM2 and
TM3. Thus, the ferrocenyl carboxamide 5b (FAUC 185) was
identified as a synthetic agonist that is able to stimulate the mutant
receptor in a manner similar to that by which endogenous dopamine
activates the D2L wild-type receptor. The engineered dopamine
receptor D2L F3906.52W in combination with FAUC
185 (5b) provides a new tool to probe GPCR functions
selectively in specific cell populations in vitro and in vivo.</dcterms:abstract>
        <bib:pages>25-35</bib:pages>
        <dc:date>2009-09-24</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368624/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778805
PMCID: PMC3368624</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9245">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368624/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368667/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000167</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ulness</foaf:surname>
                        <foaf:givenname>Darin J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mach</foaf:surname>
                        <foaf:givenname>Julie R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7084"/>
        <dc:title>Establishment of a Neurochemistry Track under the New ACS Guidelines</dc:title>
        <dcterms:abstract>, The new guidelines put forth by the ACS for approved chemistry degrees provide departments with greater flexibility in designing their ACS majors. Under these guidelines, students receive foundational and in-depth chemistry training while allowing individual departments to use their creativity in developing a curriculum that best meets the needs of their students and plays to the strength of the department. The chemistry department at Concordia College has developed an ACS Neurochemistry track and shares how the program arose, some of the practical matters in developing it, and how it can be made to work well within a liberal arts college.</dcterms:abstract>
        <bib:pages>259-262</bib:pages>
        <dc:date>2010-03-08</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368667/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778825
PMCID: PMC3368667</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7084">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368667/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843921/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900025j</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Balboni</foaf:surname>
                        <foaf:givenname>Gianfranco</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Salvadori</foaf:surname>
                        <foaf:givenname>Severo</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Trapella</foaf:surname>
                        <foaf:givenname>Claudio</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Knapp</foaf:surname>
                        <foaf:givenname>Brian I.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bidlack</foaf:surname>
                        <foaf:givenname>Jean M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lazarus</foaf:surname>
                        <foaf:givenname>Lawrence H.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Peng</foaf:surname>
                        <foaf:givenname>Xuemei</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Neumeyer</foaf:surname>
                        <foaf:givenname>John L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6576"/>
        <dc:title>Evolution of the Bifunctional Lead ? Agonist/? Antagonist Containing the 2?,6?-Dimethyl-l-tyrosine-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid (Dmt-Tic) Opioid Pharmacophore</dc:title>
        <dcterms:abstract>, Based on a renewed importance recently attributed to bi- or multifunctional opioids, we report the synthesis and pharmacological evaluation of some analogues derived from our lead μ agonist/δ antagonist, H-Dmt-Tic-Gly-NH-Bzl (Dmt = 2′,6′-dimethyl-l-tyrosine, Tic = 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, Bzl = benzyl). Our previous studies focused on the importance of the C-teminal benzyl function in the induction of such bifunctional activity. The introduction of some substituents in the para position of the phenyl ring (−Cl, −CH3, partially −NO2, inactive −NH2) was found to give a more potent μ agonist/antagonist effect associated with a relatively unmodified δ antagonist activity (pA2 = 8.28−9.02). Increasing the steric hindrance of the benzyl group (using diphenylmethyl and tetrahydroisoquinoline functionalities) substantially maintained the μ agonist and δ antagonist activities of the lead compound. Finally and quite unexpectedly d-Tic2, considered as a wrong opioid message now, inserted into the reference compound in lieu of l-Tic provided a μ agonist/δ agonist better than our reference ligand (H-Dmt-Tic-Gly-NH-Ph; Ph = phenyl) and was endowed with the same pharmacological profile.</dcterms:abstract>
        <bib:pages>155-164</bib:pages>
        <dc:date>2009-11-04</dc:date>
        <z:shortTitle>Evolution of the Bifunctional Lead ?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843921/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20352071
PMCID: PMC2843921</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6576">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843921/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368656/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>11</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000759</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Proteau-Gagne</foaf:surname>
                        <foaf:givenname>Arnaud</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bournival</foaf:surname>
                        <foaf:givenname>Veronique</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rochon</foaf:surname>
                        <foaf:givenname>Kristina</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dory</foaf:surname>
                        <foaf:givenname>Yves L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gendron</foaf:surname>
                        <foaf:givenname>Louis</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8410"/>
        <dc:title>Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the ?-Opioid Receptor</dc:title>
        <dcterms:abstract>, The role of each of the four amide bonds in Leu5-enkephalin was investigated by systematically and sequentially replacing each with its corresponding trans-alkene. Six Leu5-enkephalin analogs based on six dipeptide surrogates and two Met5-enkephalin analogs were synthesized and thoroughly tested using a δ-opioid receptor internalization assay, an ERK1/2 activation assay, and a competition binding assay to evaluate their biological properties. We observed that an E-alkene can efficiently replace the first amide bond of Leu5- and Met5-enkephalin without significantly affecting biological activity. By contrast, the second amide bond was found to be highly sensitive to the same modification, suggesting that it is involved in biologically essential intra- or intermolecular interactions. Finally, we observed that the affinity and activity of analogs containing an E-alkene at either the third or fourth position were partially reduced, indicating that these amide bonds are less important for these intra- or intermolecular interactions. Overall, our study demonstrates that the systematic and sequential replacement of amide bonds by E-alkene represents an efficient way to explore peptide backbones.</dcterms:abstract>
        <bib:pages>757-769</bib:pages>
        <dc:date>2010-09-17</dc:date>
        <z:shortTitle>Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the ?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368656/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778812
PMCID: PMC3368656</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8410">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368656/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887711/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>6</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100003u</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Maina</foaf:surname>
                        <foaf:givenname>Francis K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mathews</foaf:surname>
                        <foaf:givenname>Tiffany A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8952"/>
        <dc:title>Functional Fast Scan Cyclic Voltammetry Assay to Characterize Dopamine D2 and D3 Autoreceptors in the Mouse Striatum</dc:title>
        <dcterms:abstract>, Dopamine D2 and D3 autoreceptors are located on presynaptic terminals and are known to control the release and synthesis of dopamine. Dopamine D3 receptors have a fairly restricted pattern of expression in the mammalian brain. Their localization in the nucleus accumbens core and shell is of particular interest because of their association with the rewarding properties of drugs of abuse. Using background subtracted fast scan cyclic voltammetry, we investigated the effects of dopamine D2 and D3 agonists on electrically stimulated dopamine release and uptake rates in the mouse caudate putamen and nucleus accumbens core and shell. The dopamine D2 agonists (−)-quinpirole hydrochloride and 5,6,7,8-tetrahydro-6-(2-propen-1-yl)-4H-thiazolo[4,5-d]azepin-2-amine dihydrochloride (B-HT 920) had the same dopamine release inhibition effects on caudate putamen and nucleus accumbens (core and shell) on the basis of their EC50 values and efficacies. This suggests that the dopamine D2 autoreceptor functionality is comparable in all three striatal regions investigated. The dopamine D3 agonists (4aR,10bR)-3,4a,4,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol hydrochloride ((+)-PD 128907) and (±)-7-Hydroxy-2-dipropylaminotetralin hydrobromide (7-OH-DPAT) had a significantly greater effect on dopamine release inhibition in the nucleus accumbens shell than in the caudate putamen. This study confirms that, the dopamine D3 autoreceptor functionality is greater in the nucleus accumbens shell followed by the nucleus accumbens core, with the caudate putamen having the least. Neither dopamine D2 nor D3 agonists affected the uptake rates in nucleus accumbens but concentrations greater than 0.1 μM lowered the uptake rate in caudate putamen. To validate our method of evaluating dopamine D2 and D3 autoreceptors, sulpiride (D2 antagonist) and nafadotride (D3 antagonist) were used to reverse the effects of the dopamine agonists to approximately 100% of the preagonist dopamine release concentration. Finally, these results demonstrate a functional voltammetric assay that characterizes dopamine D2-like agonists as either D2- or D3-preferring agonists by taking advantage of the unique receptor density within the striatum.</dcterms:abstract>
        <bib:pages>450-462</bib:pages>
        <dc:date>2010-03-12</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887711/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20567609
PMCID: PMC2887711</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8952">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887711/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368659/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100017a</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_5806"/>
        <dc:title>GlyT1 - Up from the Ashes. The Importance of Not Condemning a Mechanism Based on a Single Chemotype</dc:title>
        <bib:pages>165-166</bib:pages>
        <dc:date>2010-03-17</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368659/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778822
PMCID: PMC3368659</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_5806">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368659/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908422/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn9000268</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hooker</foaf:surname>
                        <foaf:givenname>Jacob M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenname>Sung Won</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Alexoff</foaf:surname>
                        <foaf:givenname>David</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xu</foaf:surname>
                        <foaf:givenname>Youwen</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shea</foaf:surname>
                        <foaf:givenname>Colleen</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Reid</foaf:surname>
                        <foaf:givenname>Alicia</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Volkow</foaf:surname>
                        <foaf:givenname>Nora</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fowler</foaf:surname>
                        <foaf:givenname>Joanna S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8339"/>
        <dc:title>Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission Tomography</dc:title>
        <dcterms:abstract>, MS-275 (entinostat) is a histone deacetylase (HDAC) inhibitor currently in clinical trials for the treatment of several types of cancer. Recent reports have noted that MS-275 can cross the blood−brain barrier (BBB) and cause region-specific changes in rodent brain histone acetylation. To characterize the pharmacokinetics and distribution of MS-275 in the brain using positron emission tomography (PET), we labeled the carbamate carbon of MS-275 with carbon-11. Using PET, we determined that [11C]MS-275 has low uptake in brain tissue when administered intravenously to nonhuman primates. In rodent studies, we observed that pharmacokinetics and brain accumulation of [11C]MS-275 were not changed by the coadministration of large doses of unlabeled MS-275. These results, which both highlight the poor brain penetration of MS-275, clearly suggest its limitation as a therapeutic agent for the central nervous system (CNS). Moreover, our study demonstrates the effectiveness of PET at providing brain pharmacokinetic data for HDAC inhibitors. These data are important not only for the development of new compounds for peripheral cancer treatment (where CNS exclusion is often advantageous) but also for the treatment of neurological disorders (where CNS penetration is critical).</dcterms:abstract>
        <bib:pages>65-73</bib:pages>
        <dc:date>2009-10-21</dc:date>
        <z:shortTitle>Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908422/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20657706
PMCID: PMC2908422</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8339">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908422/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368633/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>10</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100091k</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8403"/>
        <dc:title>Horner's Syndrome and Neuroblastoma: Our Family's Odyssey with Disorders of the Sympathetic Nervous System</dc:title>
        <bib:pages>649-651</bib:pages>
        <dc:date>2010-10-20</dc:date>
        <z:shortTitle>Horner's Syndrome and Neuroblastoma</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368633/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778806
PMCID: PMC3368633</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8403">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368633/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857954/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn9000389</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mueller</foaf:surname>
                        <foaf:givenname>Ralf</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rodriguez</foaf:surname>
                        <foaf:givenname>Alice L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dawson</foaf:surname>
                        <foaf:givenname>Eric S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Butkiewicz</foaf:surname>
                        <foaf:givenname>Mariusz</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nguyen</foaf:surname>
                        <foaf:givenname>Thuy T.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Oleszkiewicz</foaf:surname>
                        <foaf:givenname>Stephen</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bleckmann</foaf:surname>
                        <foaf:givenname>Annalen</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Weaver</foaf:surname>
                        <foaf:givenname>C. David</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Conn</foaf:surname>
                        <foaf:givenname>P. Jeffrey</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Meiler</foaf:surname>
                        <foaf:givenname>Jens</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_5979"/>
        <dc:title>Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening</dc:title>
        <dcterms:abstract>, Selective potentiators of glutamate response at metabotropic glutamate receptor subtype 5 (mGluR5) have exciting potential for the development of novel treatment strategies for schizophrenia. A total of 1,382 compounds with positive allosteric modulation (PAM) of the mGluR5 glutamate response were identified through high-throughput screening (HTS) of a diverse library of 144,475 substances utilizing a functional assay measuring receptor-induced intracellular release of calcium. Primary hits were tested for concentration-dependent activity, and potency data (EC50 values) were used for training artificial neural network (ANN) quantitative structure−activity relationship (QSAR) models that predict biological potency from the chemical structure. While all models were trained to predict EC50, the quality of the models was assessed by using both continuous measures and binary classification. Numerical descriptors of chemical structure were used as input for the machine learning procedure and optimized in an iterative protocol. The ANN models achieved theoretical enrichment ratios of up to 38 for an independent data set not used in training the model. A database of ∼450,000 commercially available drug-like compounds was targeted in a virtual screen. A set of 824 compounds was obtained for testing based on the highest predicted potency values. Biological testing found 28.2% (232/824) of these compounds with various activities at mGluR5 including 177 pure potentiators and 55 partial agonists. These results represent an enrichment factor of 23 for pure potentiation of the mGluR5 glutamate response and 30 for overall mGluR5 modulation activity when compared with those of the original mGluR5 experimental screening data (0.94% hit rate). The active compounds identified contained 72% close derivatives of previously identified PAMs as well as 28% nontrivial derivatives of known active compounds.</dcterms:abstract>
        <bib:pages>288-305</bib:pages>
        <dc:date>2010-04-21</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857954/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20414370
PMCID: PMC2857954</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_5979">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2857954/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368652/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>12</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100073x</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Quek</foaf:surname>
                        <foaf:givenname>Gracia X. J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lin</foaf:surname>
                        <foaf:givenname>Diana</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Halliday</foaf:surname>
                        <foaf:givenname>Jill I.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Absalom</foaf:surname>
                        <foaf:givenname>Nathan</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ambrus</foaf:surname>
                        <foaf:givenname>Joseph I.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Thompson</foaf:surname>
                        <foaf:givenname>Andrew J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lochner</foaf:surname>
                        <foaf:givenname>Martin</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lummis</foaf:surname>
                        <foaf:givenname>Sarah C. R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>McLeod</foaf:surname>
                        <foaf:givenname>Malcolm D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chebib</foaf:surname>
                        <foaf:givenname>Mary</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7575"/>
        <dc:title>Identifying the Binding Site of Novel Methyllycaconitine (MLA) Analogs at ?4?2 Nicotinic Acetylcholine Receptors</dc:title>
        <dcterms:abstract>, Neuronal nicotinic acetylcholine receptors (nAChR) are ligand gated ion channels that mediate fast synaptic transmission. Methyllycaconitine (MLA) is a selective and potent antagonist of the α7 nAChR, and its anthranilate ester side-chain is important for its activity. Here we report the influence of structure on nAChR inhibition for a series of novel MLA analogs, incorporating either an alcohol or anthranilate ester side-chain to an azabicyclic or azatricyclic core against rat α7, α4β2, and α3β4 nAChRs expressed in Xenopus oocytes. The analogs inhibited ACh (EC50) within an IC50 range of 2.3−26.6 μM. Most displayed noncompetitive antagonism, but the anthranilate ester analogs exerted competitive behavior at the α7 nAChR. At α4β2 nAChRs, inhibition by the azabicyclic alcohol was voltage-dependent suggesting channel block. The channel-lining residues of α4 subunits were mutated to cysteine and the effect of azabicyclic alcohol was evaluated by competition with methanethiosulfonate ethylammonium (MTSEA) and a thiol-reactive probe in the open, closed, and desensitized states of α4β2 nAChRs. The azabicyclic alcohol was found to compete with MTSEA between residues 6′ and 13′ in a state-dependent manner, but the reactive probe only bonded with 13′ in the open state. The data suggest that the 13′ position is the dominant binding site. Ligand docking of the azabicyclic alcohol into a (α4)3(β2)2 homology model of the closed channel showed that the ligand can be accommodated at this location. Thus our data reveal distinct pharmacological differences between different nAChR subtypes and also identify a specific binding site for a noncompetitive channel blocker.</dcterms:abstract>
        <bib:pages>796-809</bib:pages>
        <dc:date>2010-10-07</dc:date>
        <z:shortTitle>Identifying the Binding Site of Novel Methyllycaconitine (MLA) Analogs at ?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368652/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778816
PMCID: PMC3368652</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7575">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368652/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368650/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900010d</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mishra</foaf:surname>
                        <foaf:givenname>Anurag</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dhingra</foaf:surname>
                        <foaf:givenname>Kirti</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schuz</foaf:surname>
                        <foaf:givenname>Almut</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Logothetis</foaf:surname>
                        <foaf:givenname>Nikos K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Canals</foaf:surname>
                        <foaf:givenname>Santiago</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8376"/>
        <dc:title>Improved Neuronal Tract Tracing with Stable Biocytin-Derived Neuroimaging Agents</dc:title>
        <dcterms:abstract>, One of the main characteristics of brains is their profuse connectivity
at different spatial scales. Understanding brain function evidently
first requires a comprehensive description of neuronal anatomical
connections. Not surprisingly a large number of histological markers
were developed over the years that can be used for tracing mono- or
polysynaptic connections. Biocytin is a classical neuroanatomical
tracer commonly used to map brain connectivity. However, the endogenous
degradation of the molecule by the action of biotinidase enzymes precludes
its applicability in long-term experiments and limits the quality
and completeness of the rendered connections. With the aim to improve
the stability of this classical tracer, two novel biocytin-derived
compounds were designed and synthesized. Here we present their greatly
improved stability in biological tissue along with retained capacity
to function as neuronal tracers. The experiments, 24 and 96 h postinjection,
demonstrated that the newly synthesized molecules yielded more detailed
and complete information about brain networks than that obtained with
conventional biocytin. Preliminary results suggest that the reported
molecular designs can be further diversified for use as multimodal
tracers in combined MRI and optical or electron microscopy experiments.</dcterms:abstract>
        <bib:pages>129-138</bib:pages>
        <dc:date>2009-10-06</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368650/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778821
PMCID: PMC3368650</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8376">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368650/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368629/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn9000395</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_9096"/>
        <dc:title>In This Issue</dc:title>
        <bib:pages>2-3</bib:pages>
        <dc:date>2010-01-20</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368629/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368629</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9096">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368629/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368648/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100006e</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_7771"/>
        <dc:title>In This Issue</dc:title>
        <bib:pages>85</bib:pages>
        <dc:date>2010-02-17</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368648/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368648</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7771">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368648/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368658/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000149</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_7485"/>
        <dc:title>In this issue - Issue 3</dc:title>
        <bib:pages>167</bib:pages>
        <dc:date>2010-03-17</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368658/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368658</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7485">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368658/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368670/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100030k</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_6692"/>
        <dc:title>In This Issue, Vol 1, Iss 4</dc:title>
        <bib:pages>258</bib:pages>
        <dc:date>2010-04-21</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368670/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368670</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6692">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368670/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368662/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>6</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100053z</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_8575"/>
        <dc:title>In This Issue, Vol 1, Iss 6</dc:title>
        <bib:pages>409</bib:pages>
        <dc:date>2010-06-16</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368662/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368662</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8575">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368662/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368678/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>7</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100064u</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mahipatra</foaf:surname>
                        <foaf:givenname>Anirban</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8498"/>
        <dc:title>In This Issue, Vol. 1, Iss 7</dc:title>
        <bib:pages>474</bib:pages>
        <dc:date>2010-07-21</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368678/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368678</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8498">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368678/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368687/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>8</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100071p</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mahapatra</foaf:surname>
                        <foaf:givenname>Anirban</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6496"/>
        <dc:title>In This Issue, Vol. 1, Iss 8</dc:title>
        <bib:pages>532</bib:pages>
        <dc:date>2010-08-18</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368687/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368687</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6496">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368687/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368675/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>5</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000414</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <link:link rdf:resource="#item_8629"/>
        <dc:title>In This Issue, Vol. 1, Iss. 5</dc:title>
        <bib:pages>344</bib:pages>
        <dc:date>2010-05-19</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368675/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368675</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8629">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368675/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368640/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>11</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100098d</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mahapatra</foaf:surname>
                        <foaf:givenname>Anirban</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8535"/>
        <dc:title>In This Issue, Vol. 1, Issue 11</dc:title>
        <bib:pages>717</bib:pages>
        <dc:date>2010-11-17</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368640/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368640</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8535">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368640/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368643/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>12</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1001045</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mahapatra</foaf:surname>
                        <foaf:givenname>Anirban</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7380"/>
        <dc:title>In This Issue, Vol. 1, Issue 12</dc:title>
        <bib:pages>774</bib:pages>
        <dc:date>2010-12-15</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368643/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368643</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7380">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368643/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368693/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>9</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000815</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mahapatra</foaf:surname>
                        <foaf:givenname>Anirban</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6712"/>
        <dc:title>In This Issue, Vol. 1, Issue 9</dc:title>
        <bib:pages>586</bib:pages>
        <dc:date>2010-09-15</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368693/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368693</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6712">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368693/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368632/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>10</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100087t</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mahipatra</foaf:surname>
                        <foaf:givenname>Anirban</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6499"/>
        <dc:title>In This Issue, Volume 1, Issue 10</dc:title>
        <bib:pages>652</bib:pages>
        <dc:date>2010-10-20</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368632/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368632</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6499">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368632/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368642/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>12</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100083a</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mamedov</foaf:surname>
                        <foaf:givenname>Ilgar</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Canals</foaf:surname>
                        <foaf:givenname>Santiago</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Henig</foaf:surname>
                        <foaf:givenname>Jorg</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Beyerlein</foaf:surname>
                        <foaf:givenname>Michael</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Murayama</foaf:surname>
                        <foaf:givenname>Yusuke</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mayer</foaf:surname>
                        <foaf:givenname>Hermann A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Logothetis</foaf:surname>
                        <foaf:givenname>Nikos K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Angelovski</foaf:surname>
                        <foaf:givenname>Goran</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7885"/>
        <dc:title>In Vivo Characterization of a Smart MRI Agent That Displays an Inverse Response to Calcium Concentration</dc:title>
        <dcterms:abstract>, Contrast agents for magnetic resonance imaging (MRI) that exhibit sensitivity toward specific ions or molecules represent a challenging but attractive direction of research. Here a Gd3+ complex linked to an aminobis(methylenephosphonate) group for chelating Ca2+ was synthesized and investigated. The longitudinal relaxivity (r1) of this complex decreases during the relaxometric titration with Ca2+ from 5.76 to 3.57 mM−1 s−1 upon saturation. The r1 is modulated by changes in the hydration number, which was confirmed by determination of the luminescence emission lifetimes of the analogous Eu3+ complex. The initial in vivo characterization of this responsive contrast agent was performed by means of electrophysiology and MRI experiments. The investigated complex is fully biocompatible, having no observable effect on neuronal function after administration into the brain ventricles or parenchyma. Distribution studies demonstrated that the diffusivity of this agent is significantly lower compared with that of gadolinium−diethylenetriaminepentaacetic acid (Gd−DTPA).</dcterms:abstract>
        <bib:pages>819-828</bib:pages>
        <dc:date>2010-10-20</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368642/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778817
PMCID: PMC3368642</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7885">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368642/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368684/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>7</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000364</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kawamura</foaf:surname>
                        <foaf:givenname>Kazunori</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Akiyama</foaf:surname>
                        <foaf:givenname>Megumi</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yui</foaf:surname>
                        <foaf:givenname>Joji</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yamasaki</foaf:surname>
                        <foaf:givenname>Tomoteru</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hatori</foaf:surname>
                        <foaf:givenname>Akiko</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kumata</foaf:surname>
                        <foaf:givenname>Katsushi</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wakizaka</foaf:surname>
                        <foaf:givenname>Hidekatsu</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Takei</foaf:surname>
                        <foaf:givenname>Makoto</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nengaki</foaf:surname>
                        <foaf:givenname>Nobuki</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yanamoto</foaf:surname>
                        <foaf:givenname>Kazuhiko</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fukumura</foaf:surname>
                        <foaf:givenname>Toshimitsu</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenname>Ming-Rong</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7037"/>
        <dc:title>In Vivo Evaluation of Limiting Brain Penetration of Probes for ?2C-Adrenoceptor Using Small-Animal Positron Emission Tomography</dc:title>
        <dcterms:abstract>, To evaluate in vivo brain penetration of α2C-adrenoceptor (α2C-AR) antagonists as a therapeutic agent, we synthesized two new 11C-labeled selective α2C-AR antagonists 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-2-aryl-7-methoxybenzofuran ([11C]MBF) and acridin-9-yl-[4-(4-methylpiperazin-1-yl)phenyl]amine ([11C]JP-1302) as α2C-AR-selective positron emission tomography (PET) probes. The radiochemical yield, specific activity, and radiochemical purity of these probes was appropriate for injection. To evaluate whether the brain penetration of these probes is related to the function of two major drug efflux transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), we performed PET studies using wild-type and P-gp/Bcrp knockout mice. In wild-type mice, the radioactivity level after injection with [11C]MBF initially increased and effluxed immediately from the brain, whereas that with [11C]JP-1302 was distributed throughout the brain. However, the regional distribution of radioactivity after injection with [11C]JP-1302 in the brain was different from that of α2C-ARs. In P-gp/Bcrp knockout mice, uptake of [11C]MBF was approximately 3.7-fold higher and that of [11C]JP-1302 was approximately 1.6-fold higher than those in wild-type mice. These results indicate that brain penetration of the two PET probes was affected by modulation of P-gp and Bcrp functions.</dcterms:abstract>
        <bib:pages>520-528</bib:pages>
        <dc:date>2010-06-02</dc:date>
        <z:shortTitle>In Vivo Evaluation of Limiting Brain Penetration of Probes for ?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368684/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778842
PMCID: PMC3368684</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7037">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368684/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885821/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>5</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn9000445</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chopra</foaf:surname>
                        <foaf:givenname>Rajiv</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vykhodtseva</foaf:surname>
                        <foaf:givenname>Natalia</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hynynen</foaf:surname>
                        <foaf:givenname>Kullervo</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7913"/>
        <dc:title>Influence of Exposure Time and Pressure Amplitude on Blood-Brain-Barrier Opening Using Transcranial Ultrasound Exposures</dc:title>
        <dcterms:abstract>, Pulsed ultrasound exposures of brain tissue in the presence of microbubble contrast agents have been shown to achieve transient focal disruption of the blood−brain barrier without significant damage to surrounding brain tissue. The effects of overall exposure duration on the extent of blood−brain barrier disruption was studied in these experiments to determine operating conditions for increasing the amount of therapeutic agents delivered to the brain. Exposures at 1.08 MHz ranging from 0.2 to 0.8 MPa in amplitude were delivered transcranially to the brains of rabbits and rats for durations ranging from 30 to 1200 s. The amount of signal enhancement on contrast-enhanced T1-weighted MR images were used to quantify the extent of blood−brain barrier disruption, and histological evaluation of the exposed regions was performed to evaluate the impact on brain tissue. A subset of four rats underwent weekly exposures for 3 weeks to evaluate the feasibility of repeat sonications to the brain. The results suggest that exposures less than 180 s in duration are associated with a low probability of irreversible damage to brain tissue at pressure amplitudes of 0.38 MPa. Although exposures greater than 300 s were associated with an increase in the proportion of irreversible damage, this may be acceptable for chemotherapy delivery, where the therapeutic goal is tissue destruction. Repeat exposures to the brain were feasible but resulted in evidence of focal brain damage in 50% of animals.</dcterms:abstract>
        <bib:pages>391-398</bib:pages>
        <dc:date>2010-03-02</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885821/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20563295
PMCID: PMC2885821</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7913">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885821/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017353/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>10</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100046m</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kumar</foaf:surname>
                        <foaf:givenname>Amit</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Moody</foaf:surname>
                        <foaf:givenname>LaMaryet</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Olaivar</foaf:surname>
                        <foaf:givenname>Jason F.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lewis</foaf:surname>
                        <foaf:givenname>Nerissa A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Khade</foaf:surname>
                        <foaf:givenname>Rahul L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Holder</foaf:surname>
                        <foaf:givenname>Alvin A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhang</foaf:surname>
                        <foaf:givenname>Yong</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rangachari</foaf:surname>
                        <foaf:givenname>Vijayaraghavan</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6730"/>
        <dc:title>Inhibition of A?42 Peptide Aggregation by a Binuclear Ruthenium(II)-Platinum(II) Complex: Potential for Multimetal Organometallics as Anti-amyloid Agents</dc:title>
        <dcterms:abstract>, Design of inhibitors for amyloid-β (Aβ) peptide aggregation has been widely investigated over the years toward developing viable therapeutic agents for Alzheimer’s disease (AD). The biggest challenge seems to be inhibiting Aβ aggregation at the early stages possibly at the monomeric level, because oligomers are known to be neurotoxic. In this regard, exploiting the metal-chelating property of Aβ to generate molecules that can overcome this impediment presents some promise. Recently, one such metal complex containing PtII ([Pt(BPS)Cl2]) was reported to effectively inhibit Aβ42 aggregation and toxicity (Barnham, et al. (2008) Proc. Natl. Acad. Sci. U.S.A.105, 681318463291). This complex was able bind to Aβ42 at the N-terminal part of the peptide and triggered a conformational change resulting in effective inhibition. In the current report, we have generated a mixed-binuclear metal complex containing PtII and RuII metal centers that inhibited Aβ42 aggregation at an early stage and seemed to have different modes of interaction than the previously reported PtII complex, suggesting an important role of the second metal center. This ‘proof-of-concept’ compound will help in developing more effective molecules against Aβ aggregation by modifying the two metal centers as well as their bridging ligands, which will open doors to new rationale for Aβ inhibition.</dcterms:abstract>
        <bib:pages>691-701</bib:pages>
        <dc:date>2010-08-23</dc:date>
        <z:shortTitle>Inhibition of A?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017353/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21221412
PMCID: PMC3017353</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6730">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017353/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368625/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900006n</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Featherstone</foaf:surname>
                        <foaf:givenname>David E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_5881"/>
        <dc:title>Intercellular Glutamate Signaling in the Nervous System and Beyond</dc:title>
        <dcterms:abstract>, Most intercellular glutamate signaling in the nervous system occurs at synapses. Some intercellular glutamate signaling occurs outside synapses, however, and even outside the nervous system where high ambient extracellular glutamate might be expected to preclude the effectiveness of glutamate as an intercellular signal. Here, I briefly review the types of intercellular glutamate signaling in the nervous system and beyond, with emphasis on the diversity of signaling mechanisms and fundamental unanswered questions.</dcterms:abstract>
        <bib:pages>4-12</bib:pages>
        <dc:date>2009-10-09</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368625/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778802
PMCID: PMC3368625</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_5881">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368625/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368649/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900005d</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jin</foaf:surname>
                        <foaf:givenname>Wu-Yang</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yu</foaf:surname>
                        <foaf:givenname>Long-Chuan</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8098"/>
        <dc:title>Involvement of Protein Kinase C in Morphine Tolerance at Spinal Levels of Rats</dc:title>
        <dcterms:abstract>, The present study was performed to investigate the possible role of protein kinase C (PKC) in morphine tolerance at spinal levels of rats. Intrathecal injection of 10 μg of morphine induced increases in the hindpaw withdrawal latency (HWL) to noxious thermal and mechanical stimulation in rats. After intrathecal injections of 10 μg of morphine (twice a day) lasted for 5 days, the antinociceptive effects induced by intrathecal injections of morphine decreased significantly in rats. Interestingly, we found that there were significant increases in the content of PKC in the dorsal horn of the spinal cord and the dorsal root ganglion, but not in the ventral horn of the spinal cord, in rats with morphine tolerance determined by Western blot, suggesting that PKC is involved in morphine tolerance at spinal levels of rats. Furthermore, our results demonstrated that chronic intrathecal injection of the PKC inhibitor significantly inhibited the development of morphine tolerance. Moreover, we found that the maintenance of morphine tolerance was blocked by intrathecal administration of a PKC inhibitor in rats, and the inhibitory effects of the PKC inhibitor on morphine tolerance lasted for more than two days. Taken together, the present study clearly showed that PKC is involved in morphine tolerance at the spinal level of rats and that intrathecal administration of a PKC inhibitor can block the development and maintenance of morphine tolerance.</dcterms:abstract>
        <bib:pages>122-128</bib:pages>
        <dc:date>2009-10-05</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368649/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778820
PMCID: PMC3368649</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8098">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368649/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368679/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>8</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100048z</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lucido</foaf:surname>
                        <foaf:givenname>Anna Lisa</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gopalakrishnan</foaf:surname>
                        <foaf:givenname>Gopakumar</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yam</foaf:surname>
                        <foaf:givenname>Patricia T.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Colman</foaf:surname>
                        <foaf:givenname>David R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lennox</foaf:surname>
                        <foaf:givenname>R. Bruce</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8415"/>
        <dc:title>Isolation of Functional Presynaptic Complexes from CNS Neurons: A Cell-Free Preparation for the Study of Presynaptic Compartments In Vitro</dc:title>
        <dcterms:abstract>, The difficulty in developing successful treatments to facilitate nerve regeneration has prompted a number of new in vitro experimental methods. We have recently shown that functional presynaptic boutons can be formed when neuronal cells are cocultured with surface-modified artificial substrates including poly(d-lysine)-coated beads and supported lipid bilayer-coated beads (Lucido(2009) J. Neurosci.29, 12449−1246619812321; Gopalakrishnan(2010) ACS Chem. Neurosci.1, 86−9422778819). We demonstrate here, using confocal microscopy combined with immunocytochemistry, that it is possible to isolate such in vitro presynaptic endings in an exclusive fashion onto glass substrates through a simple “sandwich/lift-off” technique (Perez(2006) Adv. Funct. Mater.16, 306−312). Isolated presynaptic complexes are capable of releasing and recycling neurotransmitter in response to an external chemical trigger. These bead−presynaptic complexes are facile to prepare and are readily dispersible in solution. They are thus compatible with many experimental methods whose focus is the study of the neuronal presynaptic compartment.</dcterms:abstract>
        <bib:pages>535-541</bib:pages>
        <dc:date>2010-06-24</dc:date>
        <z:shortTitle>Isolation of Functional Presynaptic Complexes from CNS Neurons</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368679/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22777142
PMCID: PMC3368679</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8415">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368679/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123905/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100085g</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Patel</foaf:surname>
                        <foaf:givenname>Kush N.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dong</foaf:surname>
                        <foaf:givenname>Xinzhong</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9172"/>
        <dc:title>Itch: Cells, Molecules, and Circuits</dc:title>
        <dcterms:abstract>, The itch field has made great advances in recent years, building upon earlier work to form a clearer picture of the biology behind this important sensory modality. Models for how itch is encoded have emerged that fit with physiological, molecular, and behavioral data. The molecular mechanisms of itch, both peripherally and centrally, are being revealed with the aid of newer animal models. Future work must address shortcomings in our current understanding of itch including limitations of current experimental methods. Here we review what is known about the cells, molecules, and circuits involved in itch and highlight key questions that remain to be answered.</dcterms:abstract>
        <bib:pages>17-25</bib:pages>
        <dc:date>2010-11-23</dc:date>
        <z:shortTitle>Itch</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123905/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21720568
PMCID: PMC3123905</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9172">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123905/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860192/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900037c</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Limon</foaf:surname>
                        <foaf:givenname>Agenor</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Reyes-Ruiz</foaf:surname>
                        <foaf:givenname>Jorge M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vaswani</foaf:surname>
                        <foaf:givenname>Rishi G.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chamberlin</foaf:surname>
                        <foaf:givenname>A. Richard</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Miledi</foaf:surname>
                        <foaf:givenname>Ricardo</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9112"/>
        <dc:title>Kaitocephalin Antagonism of Glutamate Receptors Expressed in Xenopus Oocytes</dc:title>
        <dcterms:abstract>, Kaitocephalin is the first discovered natural toxin with protective properties against excitotoxic death of cultured neurons induced by N-methyl-d-aspartate (NMDA) or α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)/kainic acid (kainate, KA) receptors. Nevertheless, the effects of kaitocephalin on the function of these receptors were unknown. In this work, we report some pharmacological properties of synthetic (−)-kaitocephalin on rat brain glutamate receptors expressed in Xenopus laevis oocytes and on the homomeric AMPA-type GluR3 and KA-type GluR6 receptors. Kaitocephalin was found to be a more potent antagonist of NMDA receptors (IC50 = 75 ± 9 nM) than of AMPA receptors from cerebral cortex (IC50 = 242 ± 37 nM) and from homomeric GluR3 subunits (IC50 = 502 ± 55 nM). Moreover, kaitocephalin is a weak antagonist of the KA-type receptor GluR6 (IC50 ∼ 100 μM) and of metabotropic (IC50 > 100 μM) glutamate receptors expressed by rat brain mRNA.</dcterms:abstract>
        <bib:pages>175-181</bib:pages>
        <dc:date>2009-12-28</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860192/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20436943
PMCID: PMC2860192</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9112">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860192/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038641/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>7</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100019g</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>McCracken</foaf:surname>
                        <foaf:givenname>L. M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>McCracken</foaf:surname>
                        <foaf:givenname>M. L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gong</foaf:surname>
                        <foaf:givenname>D. H.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Trudell</foaf:surname>
                        <foaf:givenname>J. R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Harris</foaf:surname>
                        <foaf:givenname>R. A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8720"/>
        <dc:title>Linking of Glycine Receptor Transmembrane Segments Three and Four Allows Assignment of Intrasubunit-Facing Residues</dc:title>
        <dcterms:abstract>, Glycine receptors (GlyRs) are pentameric ligand-gated ion channels that mediate inhibitory neurotransmission in the brain and spinal cord and are targets of alcohols and anesthetics. The transmembrane (TM) domain of GlyR subunits is composed of four α-helical segments (TM1−4), but there are conflicting data about the orientation of TM3 and TM4 and, therefore, also the proximity of residues (e.g., A288) that are important for alcohol and anesthetic effects. In the present study, we investigated the proximity of A288 in TM3 to residues in TM4 from M404 to K411. We generated eight double mutant GlyRs (A288C/M404C, A288C/F405C, A288C/Y406C, A288C/W407C, A288C/I408C, A288C/I409C, A288C/Y410C, and A288C/K411C), as well as the corresponding single mutants, and expressed them in Xenopus laevis oocytes. To measure glycine responses, we used two-electrode voltage clamp electrophysiology. We built homology models of the GlyR using structures of the nicotinic acetylcholine receptor (nAChR) and a prokaryotic ion channel (Gloeobacter violaceus, GLIC) as templates, and asked which model best fit our experimental data. Application of the cross-linking reagent HgCl2 in the closed state produced a leftward shift in the glycine concentration−response curves of the A288C/W407C and A288C/Y410C mutants, suggesting they are able to form cross-links. In addition, when HgCl2 was coapplied with glycine, responses were changed in the A288C/Y406C, A288C/I409C, and A288C/Y410C double mutants, suggesting that agonist-induced rotation of TM4 allows A288C/Y406C and A288C/I409C to cross-link. These results are consistent with a model of GlyR, based on nAChR, in which A288, Y406, W407, I409, and Y410 face into a four-helical bundle.</dcterms:abstract>
        <bib:pages>482-494</bib:pages>
        <dc:date>2010-04-12</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038641/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21326622
PMCID: PMC3038641</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8720">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038641/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368651/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900011n</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gopalakrishnan</foaf:surname>
                        <foaf:givenname>Gopakumar</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Thostrup</foaf:surname>
                        <foaf:givenname>Peter</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rouiller</foaf:surname>
                        <foaf:givenname>Isabelle</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lucido</foaf:surname>
                        <foaf:givenname>Anna Lisa</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Belkaid</foaf:surname>
                        <foaf:givenname>Wiam</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Colman</foaf:surname>
                        <foaf:givenname>David R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lennox</foaf:surname>
                        <foaf:givenname>R. Bruce</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8049"/>
        <dc:title>Lipid Bilayer Membrane-Triggered Presynaptic Vesicle Assembly</dc:title>
        <dcterms:abstract>, The formation of functional synapses on artificial substrates is a very important step in the development of engineered in vitro neural networks. Spherical supported bilayer lipid membranes (SS-BLMs) are used here as a novel substrate to demonstrate presynaptic vesicle accumulation at an in vitro synaptic junction. Confocal fluorescence microscopy, cryo-transmission electron microscopy (cryo-TEM), and fluorescence recovery after photobleaching (FRAP) experiments have been used to characterize the SS-BLMs. Conventional immunocytochemistry combined with confocal fluorescence microscopy was used to observe the formation of presynaptic vesicles at the neuron−SS-BLM contacts. These results indicate that lipid phases may play a role in the observed phenomenon, in addition to the chemical and electrostatic interactions between the neurons and SS-BLMs. The biocompatibility of lipid bilayers along with their membrane tunability makes the suggested approach a useful “toolkit” for many neuroengineering applications including artificial synapse formation and synaptogenesis in vivo.</dcterms:abstract>
        <bib:pages>86-94</bib:pages>
        <dc:date>2009-10-15</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368651/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778819
PMCID: PMC3368651</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8049">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368651/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368660/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900021z</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Carmona</foaf:surname>
                        <foaf:givenname>Asuncion</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Deves</foaf:surname>
                        <foaf:givenname>Guillaume</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Roudeau</foaf:surname>
                        <foaf:givenname>Stephane</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cloetens</foaf:surname>
                        <foaf:givenname>Peter</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bohic</foaf:surname>
                        <foaf:givenname>Sylvain</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ortega</foaf:surname>
                        <foaf:givenname>Richard</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8536"/>
        <dc:title>Manganese Accumulates within Golgi Apparatus in Dopaminergic Cells as Revealed by Synchrotron X-ray Fluorescence Nanoimaging</dc:title>
        <dcterms:abstract>, Chronic exposure to manganese results in neurological symptoms referred to as manganism and is identified as a risk factor for Parkinson’s disease. In vitro, manganese induces cell death in the dopaminergic cells, but the mechanisms of manganese cytotoxicity are still unexplained. In particular, the subcellular distribution of manganese and its interaction with other trace elements needed to be assessed. Applying synchrotron X-ray fluorescence nanoimaging, we found that manganese was located within the Golgi apparatus of PC12 dopaminergic cells at physiologic concentrations. At increasing concentrations, manganese accumulates within the Golgi apparatus until cytotoxic concentrations are reached resulting in a higher cytoplasmic content probably after the Golgi apparatus storage capacity is exceeded. Cell exposure to manganese and brefeldin A, a molecule known to specifically cause the collapse of the Golgi apparatus, results in the striking intracellular redistribution of manganese, which accumulates in the cytoplasm and the nucleus. These results indicate that the Golgi apparatus plays an important role in the cellular detoxification of manganese. In addition manganese exposure induces a decrease in total iron content, which could contribute to the overall neurotoxicity.</dcterms:abstract>
        <bib:pages>194-203</bib:pages>
        <dc:date>2009-12-17</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368660/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778823
PMCID: PMC3368660</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8536">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368660/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929024/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>7</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000217</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jarecki</foaf:surname>
                        <foaf:givenname>Jessica L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Andersen</foaf:surname>
                        <foaf:givenname>Kari</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Konop</foaf:surname>
                        <foaf:givenname>Christopher J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Knickelbine</foaf:surname>
                        <foaf:givenname>Jennifer J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vestling</foaf:surname>
                        <foaf:givenname>Martha M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Stretton</foaf:surname>
                        <foaf:givenname>Antony O.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6472"/>
        <dc:title>Mapping Neuropeptide Expression by Mass Spectrometry in Single Dissected Identified Neurons from the Dorsal Ganglion of the Nematode Ascaris suum</dc:title>
        <dcterms:abstract>, We have developed a method for dissecting single neurons from the nematode Ascaris suum, in order to determine their peptide content by mass spectrometry (MS). In this paper, we use MALDI-TOF MS and tandem MS to enumerate and sequence the peptides present in the two neurons, ALA and RID, that comprise the dorsal ganglion. We compare the peptide content determined by MS with the results of immunocytochemistry and in situ hybridization of previously isolated peptides AF2, AF8, and six peptides encoded by the afp-1 transcript. We find complete agreement among the three techniques, which validates single neuron MS as a method for peptide localization. We also discovered and sequenced six novel peptides in the ALA neuron. Cloning of cDNAs and database searching of Genomic Survey Sequences showed that transcript afp-12 encodes peptide AF36 (VPSAADMMIRFamide) and afp-13 encodes AF19 (AEGLSSPLIRFamide), AF34 (DSKLMDPLIRFamide), AF35 (DPQQRIVTDETVLRFamide), and three nonamidated peptides (PepTT, PepTL, and PepGE). We have found no similarities with reported peptide expression in the nematode Caenorhabditis elegans. This method promises to be ideally suited for determining the peptide content of each of the 298 neurons in the nervous system of this nematode.</dcterms:abstract>
        <bib:pages>505-519</bib:pages>
        <dc:date>2010-05-03</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929024/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20806053
PMCID: PMC2929024</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6472">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929024/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369727/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1001039</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Larsen</foaf:surname>
                        <foaf:givenname>Ann M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bunch</foaf:surname>
                        <foaf:givenname>Lennart</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_5998"/>
        <dc:title>Medicinal Chemistry of Competitive Kainate Receptor Antagonists</dc:title>
        <dcterms:abstract>, Kainic acid (KA) receptors belong to the group of ionotropic
glutamate receptors and are expressed throughout in the central nervous
system (CNS). The KA receptors have been shown to be involved in neurophysiological
functions such as mossy fiber long-term potentiation (LTP) and synaptic
plasticity and are thus potential therapeutic targets in CNS diseases
such as schizophrenia, major depression, neuropathic pain and epilepsy.
Extensive effort has been made to develop subtype-selective KA receptor
antagonists in order to elucidate the physiological function of each
of the five subunits known (GluK1−5). However, to date only
selective antagonists for the GluK1 subunit have been discovered,
which underlines the strong need for continued research in this area.
The present review describes the structure−activity relationship
and pharmacological profile for 10 chemically distinct classes of
KA receptor antagonists comprising, in all, 45 compounds. To the medicinal
chemist this information will serve as reference guidance as well
as an inspiration for future effort in this field.</dcterms:abstract>
        <bib:pages>60-74</bib:pages>
        <dc:date>2010-12-10</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369727/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778857
PMCID: PMC3369727</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_5998">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369727/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368655/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>11</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100072e</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Murakami</foaf:surname>
                        <foaf:givenname>Kazuma</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Horikoshi-Sakuraba</foaf:surname>
                        <foaf:givenname>Yuko</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Murata</foaf:surname>
                        <foaf:givenname>Nakaba</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Noda</foaf:surname>
                        <foaf:givenname>Yoshihiro</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Masuda</foaf:surname>
                        <foaf:givenname>Yuichi</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kinoshita</foaf:surname>
                        <foaf:givenname>Noriaki</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hatsuta</foaf:surname>
                        <foaf:givenname>Hiroyuki</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Murayama</foaf:surname>
                        <foaf:givenname>Shigeo</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shirasawa</foaf:surname>
                        <foaf:givenname>Takuji</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shimizu</foaf:surname>
                        <foaf:givenname>Takahiko</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Irie</foaf:surname>
                        <foaf:givenname>Kazuhiro</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8688"/>
        <dc:title>Monoclonal Antibody Against the Turn of the 42-Residue Amyloid ?-Protein at Positions 22 and 23</dc:title>
        <dcterms:abstract>, Aggregation of the 42-mer amyloid β-protein (Aβ42) plays a critical role in the pathogenesis of Alzheimer’s disease (AD). We have proposed a toxic conformer with a turn at positions 22 and 23, as well as a nontoxic conformer with a turn at positions 25 and 26, in Aβ42 aggregates from systematic proline scanning and solid-state NMR studies. Although recent clinical trials of immunization targeting Aβ42 aggregates have proved useful, some adverse effects were reported. One of the reasons was hypothesized to be excessive immunoreactions derived from the unintended removal of nontoxic Aβ42, which plays an important role in the physiological function. To develop a monoclonal antibody for toxic Aβ42, E22P-Aβ10-35, a minimum moiety for neurotoxicity containing the turn at positions 22 and 23, was used for the generation of antibodies, following the selection of clones using Aβ42 mutants of E22P (turn-inducing) and E22V (turn-preventing). The obtained clone (11A1) showed a high binding affinity (KD = 10.3 nM) for Aβ42 using surface plasmon resonance. 11A1 also inhibited the neurotoxicity of Aβ42 in PC12 cells. Immunohistochemical studies showed that not only extracellular but intracellular amyloid was stained in human AD brains. In Western blotting analyses using human brains, low-molecular weight-oligomers rather than the monomer of Aβ were readily recognized by 11A1. These results imply that 11A1 could detect toxic Aβ42 oligomers with the turn at positions 22 and 23 and that 11A1 could be applicable for the therapeutic targeting of toxic Aβ42 in AD.</dcterms:abstract>
        <bib:pages>747-756</bib:pages>
        <dc:date>2010-09-28</dc:date>
        <z:shortTitle>Monoclonal Antibody Against the Turn of the 42-Residue Amyloid ?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368655/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778811
PMCID: PMC3368655</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8688">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368655/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368654/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>6</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100008c</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wager</foaf:surname>
                        <foaf:givenname>Travis T.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hou</foaf:surname>
                        <foaf:givenname>Xinjun</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Verhoest</foaf:surname>
                        <foaf:givenname>Patrick R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Villalobos</foaf:surname>
                        <foaf:givenname>Anabella</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9208"/>
        <dc:title>Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties</dc:title>
        <dcterms:abstract>, The interplay among commonly used physicochemical properties in drug design was examined and utilized to create a prospective design tool focused on the alignment of key druglike attributes. Using a set of six physicochemical parameters ((a) lipophilicity, calculated partition coefficient (ClogP); (b) calculated distribution coefficient at pH = 7.4 (ClogD); (c) molecular weight (MW); (d) topological polar surface area (TPSA); (e) number of hydrogen bond donors (HBD); (f) most basic center (pKa)), a druglikeness central nervous system multiparameter optimization (CNS MPO) algorithm was built and applied to a set of marketed CNS drugs (N = 119) and Pfizer CNS candidates (N = 108), as well as to a large diversity set of Pfizer proprietary compounds (N = 11 303). The novel CNS MPO algorithm showed that 74% of marketed CNS drugs displayed a high CNS MPO score (MPO desirability score ≥ 4, using a scale of 0−6), in comparison to 60% of the Pfizer CNS candidates. This analysis suggests that this algorithm could potentially be used to identify compounds with a higher probability of successfully testing hypotheses in the clinic. In addition, a relationship between an increasing CNS MPO score and alignment of key in vitro attributes of drug discovery (favorable permeability, P-glycoprotein (P-gp) efflux, metabolic stability, and safety) was seen in the marketed CNS drug set, the Pfizer candidate set, and the Pfizer proprietary diversity set. The CNS MPO scoring function offers advantages over hard cutoffs or utilization of single parameters to optimize structure−activity relationships (SAR) by expanding medicinal chemistry design space through a holistic assessment approach. Based on six physicochemical properties commonly used by medicinal chemists, the CNS MPO function may be used prospectively at the design stage to accelerate the identification of compounds with increased probability of success.</dcterms:abstract>
        <bib:pages>435-449</bib:pages>
        <dc:date>2010-03-25</dc:date>
        <z:shortTitle>Moving beyond Rules</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368654/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778837
PMCID: PMC3368654</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9208">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368654/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860755/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900029p</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mehta</foaf:surname>
                        <foaf:givenname>Niraj R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nguyen</foaf:surname>
                        <foaf:givenname>Thien</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bullen</foaf:surname>
                        <foaf:givenname>John W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Griffin</foaf:surname>
                        <foaf:givenname>John W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schnaar</foaf:surname>
                        <foaf:givenname>Ronald L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8052"/>
        <dc:title>Myelin-Associated Glycoprotein (MAG) Protects Neurons from Acute Toxicity Using a Ganglioside-Dependent Mechanism</dc:title>
        <dcterms:abstract>, Myelin-associated glycoprotein (MAG), a protein expressed on the innermost wrap of myelin, contributes to long-term axon stability as evidenced by progressive axon degeneration in Mag-null mice. Recently, MAG was also found to protect axons from acute toxic insults. In the current study, rat dorsal root ganglion neurons were cultured on control substrata and substrata adsorbed with myelin proteins. Neurons on myelin-adsorbed surfaces were resistant to acute degeneration of neurites induced by vincristine, a cancer chemotherapeutic agent with neuropathic side effects. Myelin-mediated protection was reversed by anti-MAG antibody and was absent when cells were cultured on extracts from Mag-null mouse myelin, confirming the protective role of MAG. Gangliosides (sialylated glycosphingolipids) are one functional class of axonal receptors for MAG. In the current studies, a direct role for gangliosides in mediating the acute protective effects of MAG was established. Treatment of neurons with sialidase, an enzyme that cleaves the terminal sialic acids required for MAG binding, reversed MAG’s protective effect, as did treatment with (1R,2R)-1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol, an inhibitor of glycosphingolipid biosynthesis. In contrast, treatment with phosphatidylinositol-specific phospholipase C, an enzyme that cleaves Nogo receptors (NgR, another class of MAG receptor), or with a peptide inhibitor of an NgR-associated signaling molecule, p75NTR, failed to diminish MAG-mediated protection. Inhibiting the Rho-associated protein kinase ROCK reversed protection. We conclude that MAG protects neurites from acute toxic insult via a ganglioside-mediated signaling pathway that involves activation of RhoA. Understanding MAG-mediated protection may provide opportunities to reduce axonal damage and loss.</dcterms:abstract>
        <bib:pages>215-222</bib:pages>
        <dc:date>2009-12-29</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860755/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20436925
PMCID: PMC2860755</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8052">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860755/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368647/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>7</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000205</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Vaish</foaf:surname>
                        <foaf:givenname>Amit</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shuster</foaf:surname>
                        <foaf:givenname>Mitchell J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cheunkar</foaf:surname>
                        <foaf:givenname>Sarawut</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Singh</foaf:surname>
                        <foaf:givenname>Yogesh S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Weiss</foaf:surname>
                        <foaf:givenname>Paul S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Andrews</foaf:surname>
                        <foaf:givenname>Anne M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7662"/>
        <dc:title>Native Serotonin Membrane Receptors Recognize 5-Hydroxytryptophan-Functionalized Substrates: Enabling Small-Molecule Recognition</dc:title>
        <dcterms:abstract>, Recognition of small diffusible molecules by large biomolecules is ubiquitous in biology. To investigate these interactions, it is important to be able to immobilize small ligands on substrates; however, preserving recognition by biomolecule-binding partners under these circumstances is challenging. We have developed methods to modify substrates with serotonin, a small-molecule neurotransmitter important in brain function and psychiatric disorders. To mimic soluble serotonin, we attached its amino acid precursor, 5-hydroxytryptophan, via the ancillary carboxyl group to oligo(ethylene glycol)-terminated alkanethiols self-assembled on gold. Anti-5-hydroxytryptophan antibodies recognize these substrates, demonstrating bioavailability. Interestingly, 5-hydroxytryptophan-functionalized surfaces capture membrane-associated serotonin receptors enantiospecifically. By contrast, surfaces functionalized with serotonin itself fail to bind serotonin receptors. We infer that recognition by biomolecules evolved to distinguish small-molecule ligands in solution requires tethering of the latter via ectopic moieties. Membrane proteins, which are notoriously difficult to isolate, or other binding partners can be captured for identification, mapping, expression, and other purposes using this generalizable approach.</dcterms:abstract>
        <bib:pages>495-504</bib:pages>
        <dc:date>2010-04-09</dc:date>
        <z:shortTitle>Native Serotonin Membrane Receptors Recognize 5-Hydroxytryptophan-Functionalized Substrates</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368647/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778841
PMCID: PMC3368647</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7662">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368647/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368636/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>11</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100068x</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lawson</foaf:surname>
                        <foaf:givenname>Victoria A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Haigh</foaf:surname>
                        <foaf:givenname>Cathryn L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Roberts</foaf:surname>
                        <foaf:givenname>Blaine</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kenche</foaf:surname>
                        <foaf:givenname>Vijaya B.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Klemm</foaf:surname>
                        <foaf:givenname>Helen M. J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Masters</foaf:surname>
                        <foaf:givenname>Colin L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Collins</foaf:surname>
                        <foaf:givenname>Steven J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Barnham</foaf:surname>
                        <foaf:givenname>Kevin J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Drew</foaf:surname>
                        <foaf:givenname>Simon C.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8124"/>
        <dc:title>Near-Infrared Fluorescence Imaging of Apoptotic Neuronal Cell Death in a Live Animal Model of Prion Disease</dc:title>
        <dcterms:abstract>, Apoptotic cell death via activation of the caspase family of cysteine proteases is a common feature of many neurodegenerative diseases including Creutzfeldt−Jakob disease. Molecular imaging of cysteine protease activities at the preclinical stage may provide valuable mechanistic information about pathophysiological pathways involved in disease evolution and in response to therapy. In this study, we report synthesis and characterization of a near-infrared (NIR) fluorescent contrast agent capable of noninvasively imaging neuronal apoptosis in vivo, by conjugating a NIR cyanine dye to Val-Ala-Asp-fluoromethylketone (VAD-fmk), a general inhibitor of active caspases. Following intravenous administration of the NIR-VAD-fmk contrast agent, in vivo fluorescence reflectance imaging identified significantly higher levels of active caspases in the brain of mice with advanced but preclinical prion disease, when compared with healthy controls. The contrast agent and related analogues will enable the longitudinal study of disease progression and therapy in animal models of many neurodegenerative conditions.</dcterms:abstract>
        <bib:pages>720-727</bib:pages>
        <dc:date>2010-09-30</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368636/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778809
PMCID: PMC3368636</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8124">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368636/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873207/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>4</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900036x</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Annangudi</foaf:surname>
                        <foaf:givenname>Suresh P.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luszpak</foaf:surname>
                        <foaf:givenname>Agatha E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenname>Soong Ho</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ren</foaf:surname>
                        <foaf:givenname>Shifang</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hatcher</foaf:surname>
                        <foaf:givenname>Nathan G.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Weiler</foaf:surname>
                        <foaf:givenname>Ivan Jeanne</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Thornley</foaf:surname>
                        <foaf:givenname>Keith T.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kile</foaf:surname>
                        <foaf:givenname>Brian M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wightman</foaf:surname>
                        <foaf:givenname>R. Mark</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Greenough</foaf:surname>
                        <foaf:givenname>William T.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sweedler</foaf:surname>
                        <foaf:givenname>Jonathan V.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8453"/>
        <dc:title>Neuropeptide Release Is Impaired in a Mouse Model of Fragile X Mental Retardation Syndrome</dc:title>
        <dcterms:abstract>, Fragile X syndrome (FXS), an inherited disorder characterized by mental retardation and autism-like behaviors, is caused by the failure to transcribe the gene for fragile X mental retardation protein (FMRP), a translational regulator and transporter of select mRNAs. FXS model mice (Fmr1 KO mice) exhibit impaired neuropeptide release. Release of biogenic amines does not differ between wild-type (WT) and Fmr1 KO mice. Rab3A, an mRNA cargo of FMRP involved in the recruitment of vesicles, is decreased by ∼50% in synaptoneurosomes of Fmr1 KO mice; however, the number of dense-core vesicles (DCVs) does not differ between WT and Fmr1 KO mice. Therefore, deficits associated with FXS may reflect this aberrant vesicle release, specifically involving docking and fusion of peptidergic DCVs, and may lead to defective maturation and maintenance of synaptic connections.</dcterms:abstract>
        <bib:pages>306-314</bib:pages>
        <dc:date>2010-01-08</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873207/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20495672
PMCID: PMC2873207</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8453">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873207/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399477/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>8</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100026t</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bertaccini</foaf:surname>
                        <foaf:givenname>Edward J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Trudell</foaf:surname>
                        <foaf:givenname>James R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindahl</foaf:surname>
                        <foaf:givenname>Erik</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6272"/>
        <dc:title>Normal Mode Gating Motions of a Ligand-Gated Ion Channel Persist in a Fully Hydrated Lipid Bilayer Model</dc:title>
        <dcterms:abstract>, We have previously used molecular modeling and normal-mode analyses combined with experimental data to visualize a plausible model of a transmembrane ligand-gated ion channel. We also postulated how the gating motion of the channel may be affected by the presence of various ligands, especially anesthetics. As is typical for normal-mode analyses, those studies were performed in vacuo to reduce the computational complexity of the problem. While such calculations constitute an efficient way to model the large scale structural flexibility of transmembrane proteins, they can be criticized for neglecting the effects of an explicit phospholipid bilayer or hydrated environment. Here, we show the successful calculation of normal-mode motions for our model of a glycine α-1 receptor, now suspended in a fully hydrated lipid bilayer. Despite the almost uniform atomic density, the introduction of water and lipid does not grossly distort the overall gating motion. Normal-mode analysis revealed that even a fully immersed glycine α-1 receptor continues to demonstrate an iris-like channel gating motion as a low-frequency, high-amplitude natural harmonic vibration consistent with channel gating. Furthermore, the introduction of periodic boundary conditions allows the examination of simultaneous harmonic vibrations of lipid in synchrony with the protein gating motions that are compatible with reasonable lipid bilayer perturbations. While these perturbations tend to influence the overall protein motion, this work provides continued support for the iris-like motion model that characterizes gating within the family of ligand-gated ion channels.</dcterms:abstract>
        <bib:pages>552-558</bib:pages>
        <dc:date>2010-06-11</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399477/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22816018
PMCID: PMC3399477</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6272">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399477/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847285/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900040e</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Omiatek</foaf:surname>
                        <foaf:givenname>Donna M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dong</foaf:surname>
                        <foaf:givenname>Yan</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heien</foaf:surname>
                        <foaf:givenname>Michael L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ewing</foaf:surname>
                        <foaf:givenname>Andrew G.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_5978"/>
        <dc:title>Only a Fraction of Quantal Content is Released During Exocytosis as Revealed by Electrochemical Cytometry of Secretory Vesicles</dc:title>
        <dcterms:abstract>, The primary method for neuronal communication involves the release of chemical messengers that are packaged intracellularly in vesicles. Although experiments measuring release at single cells have classically been thought to assess the entire content of vesicles, there is evidence in the literature that suggests that the total transmitter stored in vesicles is not expelled during exocytosis. In this work, we introduce a novel technology using a microfluidic-based platform to electrochemically probe individual PC12 cell vesicles isolated from the cell environment. We measure the total vesicular content using methodology that circumvents the biophysical processes of the cell associated with exocytosis. Direct comparisons of amperometric data from release experiments at single PC12 cells versus our cell-free model reveal that on average vesicles release only 40% of their total transmitter load. The data support the intriguing hypothesis that the average vesicle does not open all the way during the normal exocytosis process, resulting in incomplete distention of the vesicular contents. In addition, we have shown that vesicular catecholamine levels can be altered with pharmacological manipulation and variances observed from these treatments can be resolved at the single vesicle level in a high-throughput manner, a process that we have termed electrochemical cytometry. Upon establishing that release in exocytotic processes proceeds in an incomplete manner, we related electrochemical data quantified from both single cell release experiments and electrochemical cytometry of vesicles to vesicular volume from electron microscopy measurements to investigate the location of intravesicular catecholamine stores retained postfusion.</dcterms:abstract>
        <bib:pages>234-245</bib:pages>
        <dc:date>2010-01-08</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847285/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20368748
PMCID: PMC2847285</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_5978">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847285/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368690/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>9</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100057j</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Aileen Funke</foaf:surname>
                        <foaf:givenname>Susanne</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>van Groen</foaf:surname>
                        <foaf:givenname>Thomas</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kadish</foaf:surname>
                        <foaf:givenname>Inga</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bartnik</foaf:surname>
                        <foaf:givenname>Dirk</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nagel-Steger</foaf:surname>
                        <foaf:givenname>Luitgard</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brener</foaf:surname>
                        <foaf:givenname>Oleksandr</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sehl</foaf:surname>
                        <foaf:givenname>Torsten</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Batra-Safferling</foaf:surname>
                        <foaf:givenname>Renu</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Moriscot</foaf:surname>
                        <foaf:givenname>Christine</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schoehn</foaf:surname>
                        <foaf:givenname>Guy</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Horn</foaf:surname>
                        <foaf:givenname>Anselm H. C.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Muller-Schiffmann</foaf:surname>
                        <foaf:givenname>Andreas</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Korth</foaf:surname>
                        <foaf:givenname>Carsten</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sticht</foaf:surname>
                        <foaf:givenname>Heinrich</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Willbold</foaf:surname>
                        <foaf:givenname>Dieter</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6060"/>
        <dc:title>Oral Treatment with the d-Enantiomeric Peptide D3 Improves the Pathology and Behavior of Alzheimer's Disease Transgenic Mice</dc:title>
        <dcterms:abstract>, Several lines of evidence suggest that the amyloid-β-peptide (Aβ) plays a central role in the pathogenesis of Alzheimer’s disease (AD). Not only Aβ fibrils but also small soluble Aβ oligomers in particular are suspected to be the major toxic species responsible for disease development and progression. The present study reports on in vitro and in vivo properties of the Aβ targeting d-enantiomeric amino acid peptide D3. We show that next to plaque load and inflammation reduction, oral application of the peptide improved the cognitive performance of AD transgenic mice. In addition, we provide in vitro data elucidating the potential mechanism underlying the observed in vivo activity of D3. These data suggest that D3 precipitates toxic Aβ species and converts them into nonamyloidogenic, nonfibrillar, and nontoxic aggregates without increasing the concentration of monomeric Aβ. Thus, D3 exerts an interesting and novel mechanism of action that abolishes toxic Aβ oligomers and thereby supports their decisive role in AD development and progression.</dcterms:abstract>
        <bib:pages>639-648</bib:pages>
        <dc:date>2010-08-02</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368690/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778851
PMCID: PMC3368690</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6060">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368690/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368677/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>5</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100044y</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mahapatra</foaf:surname>
                        <foaf:givenname>Anirban</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9260"/>
        <dc:title>Overeating, Obesity, and Dopamine Receptors</dc:title>
        <dcterms:abstract>New results in rats show that compulsive overfeeding can lead to deficits in the brain reward circuit. Interestingly, these deficits resemble those that result from drug addiction.</dcterms:abstract>
        <bib:pages>346-347</bib:pages>
        <dc:date>2010-05-19</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368677/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778831
PMCID: PMC3368677</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9260">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368677/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368680/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>8</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100052v</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Crowe</foaf:surname>
                        <foaf:givenname>Sarah E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kantevari</foaf:surname>
                        <foaf:givenname>Srinivas</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ellis-Davies</foaf:surname>
                        <foaf:givenname>Graham C. R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6877"/>
        <dc:title>Photochemically Initiated Intracellular Astrocytic Calcium Waves in Living Mice Using Two-Photon Uncaging of IP3</dc:title>
        <dcterms:abstract>, We have developed a caged IP3 analogue for two-photon photolysis in living animals. This probe is a cell permeable version and was coloaded with a fluorescent Ca2+ dye into astrocytes in layer 1 of the somatosensory cortex of anesthetized mice. Two-photon irradiation of single cells at 720 nm produced rapid and robust increases in intracellular Ca2+ concentrations monitored using two-photon microscopy at 950 nm. The photoevoked intracellular Ca2+ waves were similar in magnitude to intrinsic signals in wild type mice. These waves did not propagate to other cells beyond the targeted astrocyte. In contrast, we observed intercellular astrocytic Ca2+ waves in two mouse models of familial Alzheimer’s disease. These data suggest that Alzheimer’s might perturb gliotransmission but not IP3 signaling per se in mouse models of the disease.</dcterms:abstract>
        <bib:pages>575-585</bib:pages>
        <dc:date>2010-06-15</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368680/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778846
PMCID: PMC3368680</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6877">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368680/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974175/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>9</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100056r</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Herr</foaf:surname>
                        <foaf:givenname>Natalie R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Belle</foaf:surname>
                        <foaf:givenname>Anna M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Daniel</foaf:surname>
                        <foaf:givenname>Kevin B.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Carelli</foaf:surname>
                        <foaf:givenname>Regina M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wightman</foaf:surname>
                        <foaf:givenname>R. Mark</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6212"/>
        <dc:title>Probing Presynaptic Regulation of Extracellular Dopamine with Iontophoresis</dc:title>
        <dcterms:abstract>, Iontophoresis allows for localized drug ejections directly into brain regions of interest driven by the application of current. Our lab has previously adapted a method to quantitatively monitor iontophoretic ejections. Here those principles have been applied in vivo to modulate electrically evoked release of dopamine in anesthetized rats. A neutral, electroactive marker molecule that is ejected purely by electroosmotic flow (EOF) was used to monitor indirectly the ejection of electroinactive dopaminergic drugs (raclopride, quinpirole, and nomifensine). Electrode placements were marked with an iontophoretically ejected dye, pontamine sky blue. We show that EOF marker molecules, acetaminophen (AP) and 2-(4-nitrophenoxy) ethanol (NPE), have no effect on electrically evoked dopamine release in the striatum or the sensitivity of electrode. Additionally, we establish that a short, 30 s ejection of raclopride, quinpirole, or nomifensine with iontophoresis is sufficient to affect autoreceptor regulation and the reuptake of dopamine. These effects vary in lifetime, indicating that this technique can be used to study receptor kinetics.</dcterms:abstract>
        <bib:pages>627-638</bib:pages>
        <dc:date>2010-07-28</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974175/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21060714
PMCID: PMC2974175</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6212">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974175/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880821/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900016z</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ye</foaf:surname>
                        <foaf:givenname>Xiaoying</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Xie</foaf:surname>
                        <foaf:givenname>Fang</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Romanova</foaf:surname>
                        <foaf:givenname>Elena V.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rubakhin</foaf:surname>
                        <foaf:givenname>Stanislav S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sweedler</foaf:surname>
                        <foaf:givenname>Jonathan V.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7073"/>
        <dc:title>Production of Nitric Oxide within the Aplysia californica Nervous System</dc:title>
        <dcterms:abstract>, Nitric oxide (NO), an intercellular signaling molecule, helps coordinate neuronal network activity. Here we examine NO generation in the Aplysia californica central nervous system using 4,5-diaminofluorescein diacetate (DAF-2 DA), a fluorescent reagent that forms 4,5-diaminofluorescein triazole (DAF-2T) upon reaction with NO. Recognizing that other fluorescence products are formed within the biochemically complex intracellular environment, we validate the observed fluorescence as being from DAF-2T; using both capillary electrophoresis and mass spectrometry we confirm that DAF-2T is formed from tissues and cells exposed to DAF-2 DA. We observe three distinct subcellular distributions of fluorescence in neurons exposed to DAF-2 DA. The first shows uniform fluorescence inside the cell, with these cells being among previously confirmed NO synthase (NOS)-positive regions in the Aplysia cerebral ganglion. The second, seen inside buccal neurons, exhibits point sources of fluorescence, 1.5 ± 0.7 μm in diameter. Interestingly, the number of fluorescence puncta increases when the tissue is preincubated with the NOS substrate l-arginine, and they disappear when cells are preexposed to the NOS inhibitor l-nitro-arginine methyl ester (l-NAME), demonstrating that the fluorescence is connected to NOS-dependent NO production. The third distribution type, seen in the R2 neuron, also exhibits fluorescent puncta but only on the cell surface. Fluorescence is also observed in the terminals of cultured bag cell neurons loaded with DAF-2 DA. Surprisingly, fluorescence at the R2 surface and bag cell neuron terminals is not modulated by l-arginine or l-NAME, suggesting that it has a source distinct from the buccal and cerebral ganglion DAF 2T-positive tissues.</dcterms:abstract>
        <bib:pages>182-193</bib:pages>
        <dc:date>2009-12-03</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880821/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20532188
PMCID: PMC2880821</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7073">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880821/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369731/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000827</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Waiskopf</foaf:surname>
                        <foaf:givenname>Nir</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shweky</foaf:surname>
                        <foaf:givenname>Itzhak</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lieberman</foaf:surname>
                        <foaf:givenname>Itai</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Banin</foaf:surname>
                        <foaf:givenname>Uri</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Soreq</foaf:surname>
                        <foaf:givenname>Hermona</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9088"/>
        <dc:title>Quantum Dot Labeling of Butyrylcholinesterase Maintains Substrate and Inhibitor Interactions and Cell Adherence Features</dc:title>
        <dcterms:abstract>, Butyrylcholinesterase (BChE) is the major acetylcholine hydrolyzing enzyme in peripheral mammalian systems. It can either reside in the circulation or adhere to cells and tissues and protect them from anticholinesterases, including insecticides and poisonous nerve gases. In humans, impaired cholinesterase functioning is causally involved in many pathologies, including Alzheimer’s and Parkinson’s diseases, trait anxiety, and post stroke conditions. Recombinant cholinesterases have been developed for therapeutic use; therefore, it is important to follow their in vivo path, location, and interactions. Traditional labeling methods, such as fluorescent dyes and proteins, generally suffer from sensitivity to environmental conditions, from proximity to different molecules or special enzymes which can alter them, and from relatively fast photobleaching. In contrast, emerging development in synthesis and surface engineering of semiconductor nanocrystals enable their use to detect and follow molecules in biological milieus at high sensitivity and in real time. Therefore, we developed a platform for conjugating highly purified recombinant human BChE dimers (rhBChE) to CdSe/CdZnS quantum dots (QDs). We report the development and characterization of highly fluorescent aqueous soluble QD-rhBChE conjugates, present maintenance of hydrolytic activity, inhibitor sensitivity, and adherence to the membrane of cultured live cells of these conjugates, and outline their advantageous features for diverse biological applications.</dcterms:abstract>
        <bib:pages>141-150</bib:pages>
        <dc:date>2010-12-14</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369731/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778863
PMCID: PMC3369731</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9088">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369731/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889702/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>6</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn9000318</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Williams</foaf:surname>
                        <foaf:givenname>Richard</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zhou</foaf:surname>
                        <foaf:givenname>Ya</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Niswender</foaf:surname>
                        <foaf:givenname>Colleen M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Luo</foaf:surname>
                        <foaf:givenname>Qingwei</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Conn</foaf:surname>
                        <foaf:givenname>P. Jeffrey</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hopkins</foaf:surname>
                        <foaf:givenname>Corey R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8358"/>
        <dc:title>Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4</dc:title>
        <dcterms:abstract>, This paper describes a detailed structure−activity relationship (SAR) analysis of the metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator, (−)-N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC). We have now developed compounds with improved potency and efficacy; in addition, compounds are presented that show selectivity for mGluR4 versus the other mGluR subtypes.</dcterms:abstract>
        <bib:pages>411-419</bib:pages>
        <dc:date>2010-03-08</dc:date>
        <z:shortTitle>Re-exploration of the PHCCC Scaffold</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889702/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20582156
PMCID: PMC2889702</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8358">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2889702/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843925/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900032u</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Indarte</foaf:surname>
                        <foaf:givenname>Martin</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenname>Yi</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Madura</foaf:surname>
                        <foaf:givenname>Jeffry D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Surratt</foaf:surname>
                        <foaf:givenname>Christopher K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7403"/>
        <dc:title>Receptor-Based Discovery of a Plasmalemmal Monoamine Transporter Inhibitor via High-Throughput Docking and Pharmacophore Modeling</dc:title>
        <dcterms:abstract>, Recognition of psychostimulants such as cocaine and the amphetamines by the dopamine transporter (DAT) protein is principally responsible for the euphoria and addiction associated with these drugs. Using as a template the crystal structure of a distantly related bacterial leucine transporter, we have generated 3-D DAT computer molecular models. Ligand docking to such models has revealed potential substrate and inhibitor binding pockets, subsequently confirmed by in vitro pharmacology. An inhibitor pocket defined by the DAT model to be within the “extracellular vestibule”, just to the extracellular side of the external gate of the primary substrate pocket, was used for virtual screening of a structural library of compounds. High-throughput docking and application of pharmacophore constraints within this vestibular inhibitor pocket identified a compound structurally dissimilar to the classic monoamine (dopamine, norepinephrine, and serotonin) transporter (MAT) inhibitors. The compound displaced binding of radiolabeled cocaine analogs at all three MATs, usually with nanomolar Ki values and within 2-fold of cocaine’s affinity at the norepinephrine transporter. Although a very weak dopamine uptake inhibitor itself, this compound reduced by 3-fold the potency of cocaine in inhibiting DAT-mediated cellular uptake of dopamine. To our knowledge, the present findings are the first to successfully employ “receptor-based” computer modeling to identify moderate- to high-affinity MAT ligands. In silico ligand screening using MAT models provides a rapid, low-cost discovery process that should accelerate identification of novel ligand scaffolds and provide lead compounds in combating psychostimulant addiction and in treating other monoamine-related CNS diseases.</dcterms:abstract>
        <bib:pages>223-233</bib:pages>
        <dc:date>2010-01-05</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843925/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20352074
PMCID: PMC2843925</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7403">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843925/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368639/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>5</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900022w</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jeng</foaf:surname>
                        <foaf:givenname>Winnie</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wells</foaf:surname>
                        <foaf:givenname>Peter G.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7670"/>
        <dc:title>Reduced 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)-Initiated Oxidative DNA Damage and Neurodegeneration in Prostaglandin H Synthase-1 Knockout Mice</dc:title>
        <dcterms:abstract>, The neurodegenerative potential of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and underlying mechanisms are under debate. Here, we show that MDMA is a substrate for CNS prostaglandin H synthase (PHS)-catalyzed bioactivation to a free radical intermediate that causes reactive oxygen species (ROS) formation and neurodegenerative oxidative DNA damage. In vitro PHS-1-catalyzed bioactivation of MDMA stereoselectively produced free radical intermediate formation and oxidative DNA damage that was blocked by the PHS inhibitor eicosatetraynoic acid. In vivo, MDMA stereoselectively caused gender-independent DNA oxidation and dopaminergic nerve terminal degeneration in several brain regions, dependent on regional PHS-1 levels. Conversely, MDMA-initiated striatal DNA oxidation, nerve terminal degeneration, and motor coordination deficits were reduced in PHS-1 +/− and −/− knockout mice in a gene dose-dependent fashion. These results confirm the neurodegenerative potential of MDMA and provide the first direct evidence for a novel molecular mechanism involving PHS-catalyzed formation of a neurotoxic MDMA free radical intermediate.</dcterms:abstract>
        <bib:pages>366-380</bib:pages>
        <dc:date>2010-02-23</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368639/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778832
PMCID: PMC3368639</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7670">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368639/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368645/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000028</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8281"/>
        <dc:title>Screening and Beyond: New Opportunities to Advance Neuroscience Discovery</dc:title>
        <bib:pages>84</bib:pages>
        <dc:date>2010-02-17</dc:date>
        <z:shortTitle>Screening and Beyond</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368645/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778818
PMCID: PMC3368645</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8281">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368645/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368637/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>11</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100069c</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenname>Hailin</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Youdim</foaf:surname>
                        <foaf:givenname>Moussa B. H.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fridkin</foaf:surname>
                        <foaf:givenname>Mati</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6146"/>
        <dc:title>Selective Acetylcholinesterase Inhibitor Activated by Acetylcholinesterase Releases an Active Chelator with Neurorescuing and Anti-Amyloid Activities</dc:title>
        <dcterms:abstract>, The finding that acetylcholinesterase (AChE) colocalizes with β-amyloid (Aβ) and promotes and accelerates Aβ aggregation has renewed an intense interest in developing new multifunctional AChE inhibitors as potential disease-modifying drugs for Alzheimer’s therapy. To this end, we have developed a new class of selective AChE inhibitors with site-activated chelating activity. The identified lead, HLA20A, exhibits little affinity for metal (Fe, Cu, and Zn) ions but can be activated following inhibition of AChE to liberate an active chelator, HLA20. HLA20 has been shown to possess neuroprotective and neurorescuing activities in vitro and in vivo with the ability to lower amyloid precursor holoprotein (APP) expression and Aβ generation and inhibit Aβ aggregation induced by metal (Fe, Cu, and Zn) ion. HLA20A inhibited AChE in a time and concentration dependent manner with an HLA20A−AChE complex constant (Ki) of 9.66 × 10−6 M, a carbamylation rate (k+2) of 0.14 min−1, and a second-order rate (ki) of 1.45 × 10 4 M−1 min−1, comparable to those of rivastigmine. HLA20A showed little iron-binding capacity and activity against iron-induced lipid peroxidation (LPO) at concentrations of 1−50 μM, while HLA20 exhibited high potency in iron-binding and in inhibiting iron-induced LPO. At a concentration of 10 μM, HLA20A showed some activity against monoamine oxidase (MAO)-A and -B when tested in rat brain homogenates. Defined restrictively by Lipinski’s rules, both HLA20A and HLA20 satisfied drug-like criteria and possible oral and brain permeability, but HLA20A was more lipophilic and considerably less toxic in human SHSY5Y neuroblastoma cells at high concentrations (25 or 50 μM). Together our data suggest that HLA20A may represent a promising lead for further development for Alzheimer's disease therapy.</dcterms:abstract>
        <bib:pages>737-746</bib:pages>
        <dc:date>2010-10-04</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368637/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778810
PMCID: PMC3368637</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6146">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368637/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992437/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>8</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100040h</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>McCoy</foaf:surname>
                        <foaf:givenname>Joshua G.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Marugan</foaf:surname>
                        <foaf:givenname>Juan J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liu</foaf:surname>
                        <foaf:givenname>Ke</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Zheng</foaf:surname>
                        <foaf:givenname>Wei</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Southall</foaf:surname>
                        <foaf:givenname>Noel</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Huang</foaf:surname>
                        <foaf:givenname>Wenwei</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heilig</foaf:surname>
                        <foaf:givenname>Markus</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Austin</foaf:surname>
                        <foaf:givenname>Christopher P.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8604"/>
        <dc:title>Selective Modulation of Gq/Gs pathways by Naphtho Pyrano Pyrimidines As Antagonists of the Neuropeptide S Receptor</dc:title>
        <dcterms:abstract>, Antagonists of the neuropeptide S receptor have been postulated as promising therapeutics in the treatment of respiratory, sleep, anxiety, and addictive disorders. Here, we present the SAR of a new series of orthosteric antagonists. Neuropeptide S receptor signaling is coupled to both Gq and Gs proteins, and we observe that different analogues in this structural series can selectively antagonize these two pathways. Many G-protein coupled receptors transduce signals through multiple pathways. Selective antagonism of these pathways may lead the way to the development of more targeted pharmacological profiles and therapies.</dcterms:abstract>
        <bib:pages>559-574</bib:pages>
        <dc:date>2010-06-22</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992437/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21116448
PMCID: PMC2992437</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8604">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992437/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841011/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>3</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900034p</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Diao</foaf:surname>
                        <foaf:givenname>Jiajie</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Su</foaf:surname>
                        <foaf:givenname>Zengliu</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lu</foaf:surname>
                        <foaf:givenname>Xiaobing</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yoon</foaf:surname>
                        <foaf:givenname>Tae-Young</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shin</foaf:surname>
                        <foaf:givenname>Yeon-Kyun</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ha</foaf:surname>
                        <foaf:givenname>Taekjip</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7265"/>
        <dc:title>Single-Vesicle Fusion Assay Reveals Munc18-1 Binding to the SNARE Core Is Sufficient for Stimulating Membrane Fusion</dc:title>
        <dcterms:abstract>, Munc18, an essential regulatory protein for intracellular membrane fusion mediated by SNAREs, is known for stabilizing the closed conformation of syntaxin through the interaction with the N-terminal Habc domain (amino acids 28−146) of syntaxin. In addition, Munc18 accelerates membrane fusion and its interaction with SNARE core and the N-peptide (amino acids 1−24) of syntaxin is thought to be necessary for this function. Using the recently developed fluorescence resonance energy transfer assay to detect the fusion between two individual vesicles harboring cognate SNARE proteins, we studied the effect of Munc18 on the fusion induced by neuronal SNARE proteins by following the mixing of lipid molecules between the two vesicles. We found that Munc18-1 stimulates neuronal SNARE-mediated fusion not only with full-length syntaxin 1A but also with a truncated syntaxin 1A that is missing both the Habc domain and the N-peptide. The electron paramagnetic resonance analysis indicates that the SNARE core/Munc18 interaction is responsible for this stimulatory function and the membrane plays a role for establishing this interaction.</dcterms:abstract>
        <bib:pages>168-174</bib:pages>
        <dc:date>2010-01-14</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841011/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20300453
PMCID: PMC2841011</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7265">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841011/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398540/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn9000236</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Yekkirala</foaf:surname>
                        <foaf:givenname>Ajay S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kalyuzhny</foaf:surname>
                        <foaf:givenname>Alexander E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Portoghese</foaf:surname>
                        <foaf:givenname>Philip S.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_9218"/>
        <dc:title>Standard Opioid Agonists Activate Heteromeric Opioid Receptors: Evidence for Morphine and [d-Ala2-MePhe4-Glyol5]Enkephalin as Selective ?-? Agonists</dc:title>
        <dcterms:abstract>, Research in the opioid field has relied heavily on the use of standard agonist ligands such as morphine, [d-Ala2-MePhe4-Glyol5]enkephalin (DAMGO), U69593, bremazocine, [d-Pen2d-Pen5]enkephalin (DPDPE), and deltorphin-II as tools for investigating the three major types of opioid receptors, MOP (μ), KOP (κ), and DOP (δ), that mediate antinociception. The functional selectivity of these ligands has been based on the assumption that opioid receptors exist as homomers. As numerous studies in cultured cells have suggested that opioid receptors can associate both as homomers and heteromers, we have investigated the selectivity of these standard ligands using intracellular calcium release and [35S]GTPγS assays in HEK-293 cells that contain singly and coexpressed opioid receptors. The present study reveals that morphine and DAMGO, traditionally classified as μ selective agonists, selectively activate μ−δ heteromeric opioid receptors with greater efficacy than homomeric opioid receptors. Moreover, standard ligands that have been widely employed as κ- and δ-selective agonists display little or no differences in the activation of homomeric and heteromeric opioid receptors. The far-reaching implications of these results are discussed.</dcterms:abstract>
        <bib:pages>146-154</bib:pages>
        <dc:date>2009-11-25</dc:date>
        <z:shortTitle>Standard Opioid Agonists Activate Heteromeric Opioid Receptors</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398540/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22816017
PMCID: PMC3398540</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_9218">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398540/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368689/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>9</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100045q</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bett</foaf:surname>
                        <foaf:givenname>Cyrus K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ngunjiri</foaf:surname>
                        <foaf:givenname>Johnpeter N.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Serem</foaf:surname>
                        <foaf:givenname>Wilson K.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fontenot</foaf:surname>
                        <foaf:givenname>Krystal R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hammer</foaf:surname>
                        <foaf:givenname>Robert P.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>McCarley</foaf:surname>
                        <foaf:givenname>Robin L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Garno</foaf:surname>
                        <foaf:givenname>Jayne C.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6202"/>
        <dc:title>Structure-Activity Relationships in Peptide Modulators of ?-Amyloid Protein Aggregation: Variation in ?,?-Disubstitution Results in Altered Aggregate Size and Morphology</dc:title>
        <dcterms:abstract>, Neuronal cytotoxicity observed in Alzheimer’s disease (AD) is linked to the aggregation of β-amyloid peptide (Aβ) into toxic forms. Increasing evidence points to oligomeric materials as the neurotoxic species, not Aβ fibrils; disruption or inhibition of Aβ self-assembly into oligomeric or fibrillar forms remains a viable therapeutic strategy to reduce Aβ neurotoxicity. We describe the synthesis and characterization of amyloid aggregation mitigating peptides (AAMPs) whose structure is based on the Aβ “hydrophobic core” Aβ17−20, with α,α-disubstituted amino acids (ααAAs) added into this core as potential disrupting agents of fibril self-assembly. The number, positional distribution, and side-chain functionality of ααAAs incorporated into the AAMP sequence were found to influence the resultant aggregate morphology as indicated by ex situ experiments using atomic force microscopy (AFM) and transmission electron microscopy (TEM). For instance, AAMP-5, incorporating a sterically hindered ααAA with a diisobutyl side chain in the core sequence, disrupted Aβ1−40 fibril formation. However, AAMP-6, with a less sterically hindered ααAA with a dipropyl side chain, altered fibril morphology, producing shorter and larger sized fibrils (compared with those of Aβ1−40). Remarkably, ααAA-AAMPs caused disassembly of existing Aβ fibrils to produce either spherical aggregates or protofibrillar structures, suggesting the existence of equilibrium between fibrils and prefibrillar structures.</dcterms:abstract>
        <bib:pages>608-626</bib:pages>
        <dc:date>2010-07-08</dc:date>
        <z:shortTitle>Structure-Activity Relationships in Peptide Modulators of ?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368689/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778850
PMCID: PMC3368689</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6202">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368689/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882301/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>5</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100012x</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kiraly</foaf:surname>
                        <foaf:givenname>Drew D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Eipper-Mains</foaf:surname>
                        <foaf:givenname>Jodi E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mains</foaf:surname>
                        <foaf:givenname>Richard E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Eipper</foaf:surname>
                        <foaf:givenname>Betty A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6508"/>
        <dc:title>Synaptic Plasticity, a Symphony in GEF</dc:title>
        <dcterms:abstract>, Dendritic spines are the postsynaptic sites for the majority of excitatory synapses in the mammalian forebrain. While many spines display great stability, others change shape in a matter of seconds to minutes. These rapid alterations in dendritic spine number and size require tight control of the actin cytoskeleton, the main structural component of dendritic spines. The ability of neurons to alter spine number and size is essential for the expression of neuronal plasticity. Within spines, guanine nucleotide exchange factors (GEFs) act as critical regulators of the actin cytoskeleton by controlling the activity of Rho-GTPases. In this review, we focus on the Rho-GEFs expressed in the nucleus accumbens and localized to the postsynaptic density and, thus, positioned to effect rapid alterations in the structure of dendritic spines. We review literature that ties these GEFs to different receptor systems and intracellular signaling cascades and discuss the effects these interactions are likely to have on synaptic plasticity.</dcterms:abstract>
        <bib:pages>348-365</bib:pages>
        <dc:date>2010-03-18</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882301/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20543890
PMCID: PMC2882301</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6508">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882301/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368688/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>9</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100042d</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ono</foaf:surname>
                        <foaf:givenname>Masahiro</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ikeoka</foaf:surname>
                        <foaf:givenname>Ryoichi</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Watanabe</foaf:surname>
                        <foaf:givenname>Hiroyuki</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kimura</foaf:surname>
                        <foaf:givenname>Hiroyuki</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Fuchigami</foaf:surname>
                        <foaf:givenname>Takeshi</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Haratake</foaf:surname>
                        <foaf:givenname>Mamoru</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Saji</foaf:surname>
                        <foaf:givenname>Hideo</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nakayama</foaf:surname>
                        <foaf:givenname>Morio</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7085"/>
        <dc:title>Synthesis and Evaluation of Novel Chalcone Derivatives with 99mTc/Re Complexes as Potential Probes for Detection of ?-Amyloid Plaques</dc:title>
        <dcterms:abstract>, Four 99mTc-labeled chalcone derivatives and their corresponding rhenium analogues were tested as potential probes for imaging β-amyloid plaques. The chalcones showed higher affinity for Aβ(1−42) aggregates than did 99mTc complexes. In sections of brain tissue from an animal model of AD, the four Re chalcones intensely stained β-amyloid plaques. In biodistribution experiments using normal mice, 99mTc-BAT-chalcone ([99mTc]17) displayed high uptake in the brain (1.48% ID/g) at 2 min postinjection. The radioactivity washed out from the brain rapidly (0.17% ID/g at 60 min), a highly desirable feature for an imaging agent. [99mTc]17 may be a potential probe for imaging β-amyloid plaques in Alzheimer’s brains.</dcterms:abstract>
        <bib:pages>598-607</bib:pages>
        <dc:date>2010-07-08</dc:date>
        <z:shortTitle>Synthesis and Evaluation of Novel Chalcone Derivatives with 99mTc/Re Complexes as Potential Probes for Detection of ?</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368688/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778849
PMCID: PMC3368688</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7085">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368688/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368628/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn9000186</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kuduk</foaf:surname>
                        <foaf:givenname>Scott D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Di Marco</foaf:surname>
                        <foaf:givenname>Christina N.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bodmer-Narkevitch</foaf:surname>
                        <foaf:givenname>Vera</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cook</foaf:surname>
                        <foaf:givenname>Sean P.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Cato</foaf:surname>
                        <foaf:givenname>Matthew J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jovanovska</foaf:surname>
                        <foaf:givenname>Aneta</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Urban</foaf:surname>
                        <foaf:givenname>Mark O.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Leitl</foaf:surname>
                        <foaf:givenname>Michael</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sain</foaf:surname>
                        <foaf:givenname>Nova</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Liang</foaf:surname>
                        <foaf:givenname>Annie</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Spencer</foaf:surname>
                        <foaf:givenname>Robert H.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kane</foaf:surname>
                        <foaf:givenname>Stefanie A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hartman</foaf:surname>
                        <foaf:givenname>George D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bilodeau</foaf:surname>
                        <foaf:givenname>Mark T.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7930"/>
        <dc:title>Synthesis, Structure-Activity Relationship, and Pharmacological Profile of Analogs of The ASIC-3 Inhibitor A-317567</dc:title>
        <dcterms:abstract>, The synthesis, structure−activity relationship (SAR), and
pharmacological evaluation of analogs of the acid-sensing ion channel
(ASIC) inhibitor A-317567 are reported. It was found that the compound
with an acetylenic linkage was the most potent ASIC-3 channel blocker.
This compound reversed mechanical hypersensitivity in the rat iodoacetate
model of osteoarthritis pain, although sedation was noted. Sedation
was also observed in ASIC-3 knockout mice, questioning whether sedation
and antinociception are mediated via a non-ASIC-3 specific mechanism.</dcterms:abstract>
        <bib:pages>19-24</bib:pages>
        <dc:date>2009-10-06</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368628/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778804
PMCID: PMC3368628</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7930">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368628/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369725/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100078a</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kannan</foaf:surname>
                        <foaf:givenname>Pavitra</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Telu</foaf:surname>
                        <foaf:givenname>Sanjay</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shukla</foaf:surname>
                        <foaf:givenname>Suneet</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ambudkar</foaf:surname>
                        <foaf:givenname>Suresh V.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pike</foaf:surname>
                        <foaf:givenname>Victor W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Halldin</foaf:surname>
                        <foaf:givenname>Christer</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gottesman</foaf:surname>
                        <foaf:givenname>Michael M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Innis</foaf:surname>
                        <foaf:givenname>Robert B.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hall</foaf:surname>
                        <foaf:givenname>Matthew D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_5887"/>
        <dc:title>The &quot;Specific&quot; P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)</dc:title>
        <dcterms:abstract>, Tariquidar was developed as a specific inhibitor of the efflux transporter ABCB1. Recent positron emission tomographic brain imaging studies using [11C]tariquidar to measure ABCB1 (P-gp, P-glycoprotein) density in mice indicate that the inhibitor may not be as specific as previously thought. We examined its selectivity as an inhibitor and a substrate for the human transporters P-gp, breast cancer resistance protein (BCRP, ABCG2), and multidrug resistance protein 1 (MRP1, ABCC1). Our results show that at low concentrations, tariquidar acts selectively as an inhibitor of P-gp and also as a substrate of BCRP. At much higher concentrations (≥100 nM), tariquidar acts as an inhibitor of both P-gp and BCRP. Thus, the in vivo specificity of tariquidar depends on concentration and the relative density and capacity of P-gp vs BCRP.</dcterms:abstract>
        <bib:pages>82-89</bib:pages>
        <dc:date>2010-10-21</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369725/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778859
PMCID: PMC3369725</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_5887">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369725/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400271/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>12</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000765</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Korbas</foaf:surname>
                        <foaf:givenname>Malgorzata</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>O'Donoghue</foaf:surname>
                        <foaf:givenname>John L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Watson</foaf:surname>
                        <foaf:givenname>Gene E.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Pickering</foaf:surname>
                        <foaf:givenname>Ingrid J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Singh</foaf:surname>
                        <foaf:givenname>Satya P.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Myers</foaf:surname>
                        <foaf:givenname>Gary J.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Clarkson</foaf:surname>
                        <foaf:givenname>Thomas W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>George</foaf:surname>
                        <foaf:givenname>Graham N.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8472"/>
        <dc:title>The Chemical Nature of Mercury in Human Brain Following Poisoning or Environmental Exposure</dc:title>
        <dcterms:abstract>, Methylmercury is among the most potentially toxic species to which human populations are exposed, both at high levels through poisonings and at lower levels through consumption of fish and other seafood. However, the molecular mechanisms of methylmercury toxicity in humans remain poorly understood. We used synchrotron X-ray absorption spectroscopy (XAS) to study mercury chemical forms in human brain tissue. Individuals poisoned with high levels of methylmercury species showed elevated cortical selenium with significant proportions of nanoparticulate mercuric selenide plus some inorganic mercury and methylmercury bound to organic sulfur. Individuals with a lifetime of high fish consumption showed much lower levels of mercuric selenide and methylmercury cysteineate. Mercury exposure did not perturb organic selenium levels. These results elucidate a key detoxification pathway in the central nervous system and provide new insights into the appropriate methods for biological monitoring.</dcterms:abstract>
        <bib:pages>810-818</bib:pages>
        <dc:date>2010-10-15</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400271/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22826746
PMCID: PMC3400271</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8472">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400271/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368644/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>12</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1001057</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_5953"/>
        <dc:title>The Last Issue of Our Inaugural Year: Reflections and a View to the Future</dc:title>
        <bib:pages>770-771</bib:pages>
        <dc:date>2010-12-15</dc:date>
        <z:shortTitle>The Last Issue of Our Inaugural Year</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368644/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: null
PMCID: PMC3368644</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_5953">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368644/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368663/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>6</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn1000556</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_6766"/>
        <dc:title>The Top Prescription Drugs of 2009 in the US: CNS Therapeutics Rank among Highest Grossing</dc:title>
        <bib:pages>407-408</bib:pages>
        <dc:date>2010-06-16</dc:date>
        <z:shortTitle>The Top Prescription Drugs of 2009 in the US</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368663/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778834
PMCID: PMC3368663</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_6766">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368663/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368676/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>5</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100043n</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lindsley</foaf:surname>
                        <foaf:givenname>Craig W.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8767"/>
        <dc:title>Torn from the Headlines: AstraZeneca Fined For Illegal Marketing of SEROQUEL</dc:title>
        <bib:pages>343</bib:pages>
        <dc:date>2010-05-19</dc:date>
        <z:shortTitle>Torn from the Headlines</z:shortTitle>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368676/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778829
PMCID: PMC3368676</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8767">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368676/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843917/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>1</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn900017w</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Makos</foaf:surname>
                        <foaf:givenname>Monique A.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Han</foaf:surname>
                        <foaf:givenname>Kyung-An</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heien</foaf:surname>
                        <foaf:givenname>Michael L.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ewing</foaf:surname>
                        <foaf:givenname>Andrew G.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_7124"/>
        <dc:title>Using in Vivo Electrochemistry To Study the Physiological Effects of Cocaine and Other Stimulants on the Drosophila melanogaster Dopamine Transporter</dc:title>
        <dcterms:abstract>, Dopamine neurotransmission is thought to play a critical role in addiction, reinforcing mechanisms of drugs of abuse. Electrochemical techniques have been employed extensively for monitoring in vivo dopamine changes in the brains of model organisms including rats, mice, and primates. Here, we investigated the effects of several stimulants on dopamine clearance using recently developed microanalytical tools for in vivo electrochemical measurements of dopamine in the central nervous system of Drosophila melanogaster. A cylindrical carbon-fiber microelectrode was placed in the protocerebral anterior medial region of the Drosophila brain (an area dense with dopamine neurons), while a micropipet injector was positioned to exogenously apply dopamine. Background-subtracted fast-scan cyclic voltammetry was carried out to quantify changes in dopamine concentration in the adult fly brain. Clearance of exogenously applied dopamine was significantly decreased in the protocerebral anterior medial area of the wild-type fly following treatment with cocaine, amphetamine, methamphetamine, or methylphenidate. In contrast, dopamine uptake remained unchanged when identical treatments were employed in fumin mutant flies that lack functional dopamine transporters. Our in vivo results support in vitro binding affinity studies predicting that these four stimulants effectively block normal Drosophila dopamine transporter function. Furthermore, we found 10 μM to be a sufficient physiological cocaine concentration to significantly alter dopamine transporter uptake in the Drosophila central nervous system. Taken together, these data indicate dopamine uptake in the Drosophila brain is decreased by psychostimulants as observed in mammals. This validates the use of Drosophila as a model system for future studies into the cellular and molecular mechanisms underlying drug addiction in humans.</dcterms:abstract>
        <bib:pages>74-83</bib:pages>
        <dc:date>2009-10-26</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843917/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 20352129
PMCID: PMC2843917</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_7124">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:31:20</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843917/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369724/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS Chemical Neuroscience</dc:title>
                <prism:volume>2</prism:volume>
                <prism:number>2</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100066p</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Combs</foaf:surname>
                        <foaf:givenname>Steven</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kaufmann</foaf:surname>
                        <foaf:givenname>Kristian</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Field</foaf:surname>
                        <foaf:givenname>Julie R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Blakely</foaf:surname>
                        <foaf:givenname>Randy D.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Meiler</foaf:surname>
                        <foaf:givenname>Jens</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8095"/>
        <dc:title>Y95 and E444 Interaction Required for High-Affinity S-Citalopram Binding in the Human Serotonin Transporter</dc:title>
        <dcterms:abstract>, The human serotonin (5-hydroxytryptamine, 5-HT) transporter (hSERT) is responsible for the reuptake of 5-HT following synaptic release, as well as for import of the biogenic amine into several non-5-HT synthesizing cells including platelets. The antidepressant citalopram blocks SERT and thereby inhibits the transport of 5-HT. To identify key residues establishing high-affinity citalopram binding, we have built a comparative model of hSERT and Drosophila melanogaster SERT (dSERT) based on the Aquifex aeolicus leucine transporter (LeuTAa) crystal structure. In this study, citalopram has been docked into the homology model of hSERT and dSERT using RosettaLigand. Our models reproduce the differential binding affinities for the R- and S-isomers of citalopram in hSERT and the impact of several hSERT mutants. Species-selective binding affinities for hSERT and dSERT also can be reproduced. Interestingly, the model predicts a hydrogen bond between E444 in transmembrane domain 8 (TM8) and Y95 in TM1 that places Y95 in a downward position, thereby removing Y95 from a direct interaction with S-citalopram. Mutation of E444D results in a 10-fold reduced binding affinity for S-citalopram, supporting the hypothesis that Y95 and E444 form a stabilizing interaction in the S-citalopram/hSERT complex.</dcterms:abstract>
        <bib:pages>75-81</bib:pages>
        <dc:date>2010-10-27</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369724/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 22778858
PMCID: PMC3369724</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8095">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369724/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017368/">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <dc:title>ACS chemical neuroscience</dc:title>
                <prism:volume>1</prism:volume>
                <prism:number>11</prism:number>
                <dcterms:alternative>ACS Chem Neurosci</dcterms:alternative>
                <dc:identifier>DOI 10.1021/cn100065s</dc:identifier>
                <dc:identifier>ISSN 1948-7193</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nydegger</foaf:surname>
                        <foaf:givenname>Irma</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rumschik</foaf:surname>
                        <foaf:givenname>Sean M.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kay</foaf:surname>
                        <foaf:givenname>Alan R.</foaf:givenname>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_8753"/>
        <dc:title>Zinc is externalized rather than released during synaptic transmission</dc:title>
        <dcterms:abstract>The synaptic vesicles of some glutamatergic terminals contain a high concentration of zinc that serves functions that remain obscure. In this publication we have used the membrane permeant zinc fluophore, ZnAF-2 to determine if zinc is released during the course of synaptic transmission. Stimulation of the slices with either high potassium or electrically, leads to an increase in fluorescence that long outlasts the stimulus and remains elevated for many minutes. We demonstrate that this response is inconsistent with the free release of zinc but is with the presentation of zinc coordinated to macromolecules within the exocytosed vesicles to the extracellular space; a process we term ‘externalization’. Our data suggests a novel mechanism of synaptic transmission at zinc-rich glutamatergic terminals that distinguishes them from their metal free counterparts.</dcterms:abstract>
        <bib:pages>728-736</bib:pages>
        <dc:date>2010-9-1</dc:date>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017368/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <z:libraryCatalog>PubMed Central</z:libraryCatalog>
        <dc:description>PMID: 21221416
PMCID: PMC3017368</dc:description>
    </bib:Article>
    <z:Attachment rdf:about="#item_8753">
        <z:itemType>attachment</z:itemType>
        <dc:title>PubMed Central Link</dc:title>
        <dcterms:dateSubmitted>2014-01-12 16:29:39</dcterms:dateSubmitted>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017368/</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <link:type>text/html</link:type>
    </z:Attachment>
</rdf:RDF>
